Implantable devices which continuously monitor the electrical activity of the heart and automatically detect and terminate ventricular tachycardia (TACHYCARDIA, VENTRICULAR) and VENTRICULAR FIBRILLATION. They consist of an impulse generator, batteries, and electrodes.
Cardiac electrical stimulators that apply brief high-voltage electroshocks to the HEART. These stimulators are used to restore normal rhythm and contractile function in hearts of patients who are experiencing VENTRICULAR FIBRILLATION or ventricular tachycardia (TACHYCARDIA, VENTRICULAR) that is not accompanied by a palpable PULSE. Some defibrillators may also be used to correct certain noncritical dysrhythmias (called synchronized defibrillation or CARDIOVERSION), using relatively low-level discharges synchronized to the patient's ECG waveform. (UMDNS, 2003)
An electrical current applied to the HEART to terminate a disturbance of its rhythm, ARRHYTHMIAS, CARDIAC. (Stedman, 25th ed)
An abnormally rapid ventricular rhythm usually in excess of 150 beats per minute. It is generated within the ventricle below the BUNDLE OF HIS, either as autonomic impulse formation or reentrant impulse conduction. Depending on the etiology, onset of ventricular tachycardia can be paroxysmal (sudden) or nonparoxysmal, its wide QRS complexes can be uniform or polymorphic, and the ventricular beating may be independent of the atrial beating (AV dissociation).
A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST.
Failure of equipment to perform to standard. The failure may be due to defects or improper use.
Unexpected rapid natural death due to cardiovascular collapse within one hour of initial symptoms. It is usually caused by the worsening of existing heart diseases. The sudden onset of symptoms, such as CHEST PAIN and CARDIAC ARRHYTHMIAS, particularly VENTRICULAR TACHYCARDIA, can lead to the loss of consciousness and cardiac arrest followed by biological death. (from Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed., 2005)
Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.
A device designed to stimulate, by electric impulses, contraction of the heart muscles. It may be temporary (external) or permanent (internal or internal-external).
Cessation of heart beat or MYOCARDIAL CONTRACTION. If it is treated within a few minutes, heart arrest can be reversed in most cases to normal cardiac rhythm and effective circulation.
Injuries caused by electric currents. The concept excludes electric burns (BURNS, ELECTRIC), but includes accidental electrocution and electric shock.
Freedom of equipment from actual or potential hazards.
Surgically placed electric conductors through which ELECTRIC STIMULATION is delivered to or electrical activity is recorded from a specific point inside the body.
Removal of an implanted therapeutic or prosthetic device.
Surgically placed electric conductors through which ELECTRIC STIMULATION of nerve tissue is delivered.
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.
Methods of creating machines and devices.
The restoration of the sequential order of contraction and relaxation of the HEART ATRIA and HEART VENTRICLES by atrio-biventricular pacing.
Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY.
An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
Artificial substitutes for body parts, and materials inserted into tissue for functional, cosmetic, or therapeutic purposes. Prostheses can be functional, as in the case of artificial arms and legs, or cosmetic, as in the case of an artificial eye. Implants, all surgically inserted or grafted into the body, tend to be used therapeutically. IMPLANTS, EXPERIMENTAL is available for those used experimentally.
Regulation of the rate of contraction of the heart muscles by an artificial pacemaker.
The evaluation of incidents involving the loss of function of a device. These evaluations are used for a variety of purposes such as to determine the failure rates, the causes of failures, costs of failures, and the reliability and maintainability of devices.
A transient loss of consciousness and postural tone caused by diminished blood flow to the brain (i.e., BRAIN ISCHEMIA). Presyncope refers to the sensation of lightheadedness and loss of strength that precedes a syncopal event or accompanies an incomplete syncope. (From Adams et al., Principles of Neurology, 6th ed, pp367-9)
Surgical insertion of a prosthesis.
The artificial substitution of heart and lung action as indicated for HEART ARREST resulting from electric shock, DROWNING, respiratory arrest, or other causes. The two major components of cardiopulmonary resuscitation are artificial ventilation (RESPIRATION, ARTIFICIAL) and closed-chest CARDIAC MASSAGE.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
Types of artificial pacemakers with implantable leads to be placed at multiple intracardial sites. They are used to treat various cardiac conduction disturbances which interfere with the timing of contraction of the ventricles. They may or may not include defibrillating electrodes (IMPLANTABLE DEFIBRILLATORS) as well.
Implanted fluid propulsion systems with self-contained power source for providing long-term controlled-rate delivery of drugs such as chemotherapeutic agents or analgesics. Delivery rate may be externally controlled or osmotically or peristatically controlled with the aid of transcutaneous monitoring.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia.
Transmission of the readings of instruments to a remote location by means of wires, radio waves, or other means. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
Methods to induce and measure electrical activities at specific sites in the heart to diagnose and treat problems with the heart's electrical system.
Method in which prolonged electrocardiographic recordings are made on a portable tape recorder (Holter-type system) or solid-state device ("real-time" system), while the patient undergoes normal daily activities. It is useful in the diagnosis and management of intermittent cardiac arrhythmias and transient myocardial ischemia.
Occurrence of heart arrest in an individual when there is no immediate access to medical personnel or equipment.
A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.
The amount of BLOOD pumped out of the HEART per beat, not to be confused with cardiac output (volume/time). It is calculated as the difference between the end-diastolic volume and the end-systolic volume.
An autosomal dominant defect of cardiac conduction that is characterized by an abnormal ST-segment in leads V1-V3 on the ELECTROCARDIOGRAM resembling a right BUNDLE-BRANCH BLOCK; high risk of VENTRICULAR TACHYCARDIA; or VENTRICULAR FIBRILLATION; SYNCOPAL EPISODE; and possible sudden death. This syndrome is linked to mutations of gene encoding the cardiac SODIUM CHANNEL alpha subunit.
A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).
Characteristics of ELECTRICITY and magnetism such as charged particles and the properties and behavior of charged particles, and other phenomena related to or associated with electromagnetism.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
A generic expression for any tachycardia that originates above the BUNDLE OF HIS.
Specific practices for the prevention of disease or mental disorders in susceptible individuals or populations. These include HEALTH PROMOTION, including mental health; protective procedures, such as COMMUNICABLE DISEASE CONTROL; and monitoring and regulation of ENVIRONMENTAL POLLUTANTS. Primary prevention is to be distinguished from SECONDARY PREVENTION and TERTIARY PREVENTION.
The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)
Observation and acquisition of physical data from a distance by viewing and making measurements from a distance or receiving transmitted data from observations made at distant location.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
The abrupt cessation of all vital bodily functions, manifested by the permanent loss of total cerebral, respiratory, and cardiovascular functions.
The study of the electrical activity and characteristics of the HEART; MYOCARDIUM; and CARDIOMYOCYTES.
Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.
A type of impedance plethysmography in which bioelectrical impedance is measured between electrodes positioned around the neck and around the lower thorax. It is used principally to calculate stroke volume and cardiac volume, but it is also related to myocardial contractility, thoracic fluid content, and circulation to the extremities.
Elements of limited time intervals, contributing to particular results or situations.
Small pumps, often implantable, designed for temporarily assisting the heart, usually the LEFT VENTRICLE, to pump blood. They consist of a pumping chamber and a power source, which may be partially or totally external to the body and activated by electromagnetic motors.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
A form of CARDIAC MUSCLE disease that is characterized by ventricular dilation, VENTRICULAR DYSFUNCTION, and HEART FAILURE. Risk factors include SMOKING; ALCOHOL DRINKING; HYPERTENSION; INFECTION; PREGNANCY; and mutations in the LMNA gene encoding LAMIN TYPE A, a NUCLEAR LAMINA protein.
The use of electronic equipment to observe or record physiologic processes while the patient undergoes normal daily activities.
Persons who donate their services.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Computer systems utilized as adjuncts in the treatment of disease.
A congenital cardiomyopathy that is characterized by infiltration of adipose and fibrous tissue into the RIGHT VENTRICLE wall and loss of myocardial cells. Primary injuries usually are at the free wall of right ventricular and right atria resulting in ventricular and supraventricular arrhythmias.
Objects that produce a magnetic field.
Devices that control the supply of electric current for running electrical equipment.
Services specifically designed, staffed, and equipped for the emergency care of patients.
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. Cost effectiveness compares alternative ways to achieve a specific set of results.
An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.
Medical devices which substitute for a nervous system function by electrically stimulating the nerves directly and monitoring the response to the electrical stimulation.
Infections resulting from the implantation of prosthetic devices. The infections may be acquired from intraoperative contamination (early) or hematogenously acquired from other sites (late).
Burns produced by contact with electric current or from a sudden discharge of electricity.
Machine readable patient or equipment identification device using radio frequency from 125 kHz to 5.8 Ghz.
Electronic devices that increase the magnitude of a signal's power level or current.
Simple rapid heartbeats caused by rapid discharge of impulses from the SINOATRIAL NODE, usually between 100 and 180 beats/min in adults. It is characterized by a gradual onset and termination. Sinus tachycardia is common in infants, young children, and adults during strenuous physical activities.
The return of a sign, symptom, or disease after a remission.
Expendable and nonexpendable equipment, supplies, apparatus, and instruments that are used in diagnostic, surgical, therapeutic, scientific, and experimental procedures.
A condition in which HEART VENTRICLES exhibit impaired function.
A form of heart block in which the electrical stimulation of HEART VENTRICLES is interrupted at either one of the branches of BUNDLE OF HIS thus preventing the simultaneous depolarization of the two ventricles.
Diagnostic, therapeutic, and investigative procedures prescribed and performed by health professionals, the results of which do not justify the benefits or hazards and costs to the patient.
The restoration to life or consciousness of one apparently dead. (Dorland, 27th ed)
Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.
The systems and processes involved in the establishment, support, management, and operation of registers, e.g., disease registers.
A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY).
Application of electric current in treatment without the generation of perceptible heat. It includes electric stimulation of nerves or muscles, passage of current into the body, or use of interrupted current of low intensity to raise the threshold of the skin to pain.
The continuous measurement of physiological processes, blood pressure, heart rate, renal output, reflexes, respiration, etc., in a patient or experimental animal; includes pharmacologic monitoring, the measurement of administered drugs or their metabolites in the blood, tissues, or urine.
The prevention of recurrences or exacerbations of a disease or complications of its therapy.
Pathological conditions involving the HEART including its structural and functional abnormalities.
Delivery of health services via remote telecommunications. This includes interactive consultative and diagnostic services.
Emergency care or treatment given to a person who suddenly becomes ill or injured before full medical services become available.
The continuation of the axillary vein which follows the subclavian artery and then joins the internal jugular vein to form the brachiocephalic vein.
An impulse-conducting system composed of modified cardiac muscle, having the power of spontaneous rhythmicity and conduction more highly developed than the rest of the heart.
Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project.
The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.
The smallest difference which can be discriminated between two stimuli or one which is barely above the threshold.
First aid or other immediate intervention for accidents or medical conditions requiring immediate care and treatment before definitive medical and surgical management can be procured.
The fibrous tissue that replaces normal tissue during the process of WOUND HEALING.
Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time.
A weight-carrying structure for navigation of the air that is supported either by its own buoyancy or by the dynamic action of the air against its surfaces. (Webster, 1973)
Removal of tissue with electrical current delivered via electrodes positioned at the distal end of a catheter. Energy sources are commonly direct current (DC-shock) or alternating current at radiofrequencies (usually 750 kHz). The technique is used most often to ablate the AV junction and/or accessory pathways in order to interrupt AV conduction and produce AV block in the treatment of various tachyarrhythmias.
A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).
Malfunction of implantation shunts, valves, etc., and prosthesis loosening, migration, and breaking.
The lower right and left chambers of the heart. The right ventricle pumps venous BLOOD into the LUNGS and the left ventricle pumps oxygenated blood into the systemic arterial circulation.
The plan and delineation of prostheses in general or a specific prosthesis.
Catheters designed to be left within an organ or passage for an extended period of time.
The venous trunk of the upper limb; a continuation of the basilar and brachial veins running from the lower border of the teres major muscle to the outer border of the first rib where it becomes the subclavian vein.
NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
Criteria and standards used for the determination of the appropriateness of the inclusion of patients with specific conditions in proposed treatment plans and the criteria used for the inclusion of subjects in various clinical trials and other research protocols.
A sudden CARDIAC ARRHYTHMIA (e.g., VENTRICULAR FIBRILLATION) caused by a blunt, non-penetrating impact to the precordial region of chest wall. Commotio cordis often results in sudden death without prompt cardiopulmonary defibrillation.
A bracelet or necklace worn by an individual that alerts emergency personnel of medical information for that individual which could affect their condition or treatment.
A procedure consisting of a sequence of algebraic formulas and/or logical steps to calculate or determine a given task.
Consultation via remote telecommunications, generally for the purpose of diagnosis or treatment of a patient at a site remote from the patient or primary physician.
Fields representing the joint interplay of electric and magnetic forces.
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
The use of technology-based interventions to improve functional capacities rather than to treat disease.
Works about controlled studies which are planned and carried out by several cooperating institutions to assess certain variables and outcomes in specific patient populations, for example, a multicenter study of congenital anomalies in children.
Application of computer programs designed to assist the physician in solving a diagnostic problem.
Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table.
Migration of a foreign body from its original location to some other location in the body.
Electric conductors through which electric currents enter or leave a medium, whether it be an electrolytic solution, solid, molten mass, gas, or vacuum.
Establishment of the level of a quantifiable effect indicative of a biologic process. The evaluation is frequently to detect the degree of toxic or therapeutic effect.
Techniques using energy such as radio frequency, infrared light, laser light, visible light, or acoustic energy to transfer information without the use of wires, over both short and long distances.
The storing of visual and usually sound signals on discs for later reproduction on a television screen or monitor.
The hemodynamic and electrophysiological action of the left HEART VENTRICLE. Its measurement is an important aspect of the clinical evaluation of patients with heart disease to determine the effects of the disease on cardiac performance.
The geographic designation for states bordering on or located in the Pacific Ocean. The states so designated are Alaska, California, Hawaii, Oregon, and Washington. (U.S. Geologic Survey telephone communication)
Paramedical personnel trained to provide basic emergency care and life support under the supervision of physicians and/or nurses. These services may be carried out at the site of the emergency, in the ambulance, or in a health care institution.
The number of times the HEART VENTRICLES contract per unit of time, usually per minute.
A short vein that collects about two thirds of the venous blood from the MYOCARDIUM and drains into the RIGHT ATRIUM. Coronary sinus, normally located between the LEFT ATRIUM and LEFT VENTRICLE on the posterior surface of the heart, can serve as an anatomical reference for cardiac procedures.
The study of the heart, its physiology, and its functions.
Rhythmic compression of the heart by pressure applied manually over the sternum (closed heart massage) or directly to the heart through an opening in the chest wall (open heart massage). It is done to reinstate and maintain circulation. (Dorland, 28th ed)
A distribution in which a variable is distributed like the sum of the squares of any given independent random variable, each of which has a normal distribution with mean of zero and variance of one. The chi-square test is a statistical test based on comparison of a test statistic to a chi-square distribution. The oldest of these tests are used to detect whether two or more population distributions differ from one another.
A vehicle equipped for transporting patients in need of emergency care.
The design or construction of objects greatly reduced in scale.
Cardiac arrhythmias that are characterized by excessively slow HEART RATE, usually below 50 beats per minute in human adults. They can be classified broadly into SINOATRIAL NODE dysfunction and ATRIOVENTRICULAR BLOCK.
Methods and procedures for the diagnosis of diseases or dysfunction of the cardiovascular system or its organs or demonstration of their physiological processes.
A class of devices combining electrical and mechanical components that have at least one of the dimensions in the micrometer range (between 1 micron and 1 millimeter). They include sensors, actuators, microducts, and micropumps.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
The physical effects involving the presence of electric charges at rest and in motion.
The transference of a heart from one human or animal to another.
A condition caused by dysfunctions related to the SINOATRIAL NODE including impulse generation (CARDIAC SINUS ARREST) and impulse conduction (SINOATRIAL EXIT BLOCK). It is characterized by persistent BRADYCARDIA, chronic ATRIAL FIBRILLATION, and failure to resume sinus rhythm following CARDIOVERSION. This syndrome can be congenital or acquired, particularly after surgical correction for heart defects.
The innermost layer of the heart, comprised of endothelial cells.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
Computer-assisted processing of electric, ultrasonic, or electronic signals to interpret function and activity.
The pectoralis major and pectoralis minor muscles that make up the upper and fore part of the chest in front of the AXILLA.
Directions or principles presenting current or future rules of policy for assisting health care practitioners in patient care decisions regarding diagnosis, therapy, or related clinical circumstances. The guidelines may be developed by government agencies at any level, institutions, professional societies, governing boards, or by the convening of expert panels. The guidelines form a basis for the evaluation of all aspects of health care and delivery.
Factors which produce cessation of all vital bodily functions. They can be analyzed from an epidemiologic viewpoint.
The use of photothermal effects of LASERS to coagulate, incise, vaporize, resect, dissect, or resurface tissue.
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral and social environment; the overall condition of a human life.
Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.
Ultrasonic recording of the size, motion, and composition of the heart and surrounding tissues. The standard approach is transthoracic.
Impaired impulse conduction from HEART ATRIA to HEART VENTRICLES. AV block can mean delayed or completely blocked impulse conduction.
Feeling or emotion of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.
True-false questionnaire made up of items believed to indicate anxiety, in which the subject answers verbally the statement that describes him.
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
Artificial substitutes for body parts and materials inserted into organisms during experimental studies.
A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.
Studies determining the effectiveness or value of processes, personnel, and equipment, or the material on conducting such studies. For drugs and devices, CLINICAL TRIALS AS TOPIC; DRUG EVALUATION; and DRUG EVALUATION, PRECLINICAL are available.
The effect of environmental or physiological factors on the driver and driving ability. Included are driving fatigue, and the effect of drugs, disease, and physical disabilities on driving.
A type of automatic, not reentrant, ectopic ventricular rhythm with episodes lasting from a few seconds to a minute which usually occurs in patients with acute myocardial infarction or with DIGITALIS toxicity. The ventricular rate is faster than normal but slower than tachycardia, with an upper limit of 100 -120 beats per minute. Suppressive therapy is rarely necessary.
Summarizing techniques used to describe the pattern of mortality and survival in populations. These methods can be applied to the study not only of death, but also of any defined endpoint such as the onset of disease or the occurrence of disease complications.
General or unspecified injuries to the heart.
Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
The probability that an event will occur. It encompasses a variety of measures of the probability of a generally unfavorable outcome.
A voluntary organization concerned with the prevention and treatment of heart and vascular diseases.
Compounds based on reduced IMIDAZOLINES which contain no double bonds in the ring.
Recording of regional electrophysiological information by analysis of surface potentials to give a complete picture of the effects of the currents from the heart on the body surface. It has been applied to the diagnosis of old inferior myocardial infarction, localization of the bypass pathway in Wolff-Parkinson-White syndrome, recognition of ventricular hypertrophy, estimation of the size of a myocardial infarct, and the effects of different interventions designed to reduce infarct size. The limiting factor at present is the complexity of the recording and analysis, which requires 100 or more electrodes, sophisticated instrumentation, and dedicated personnel. (Braunwald, Heart Disease, 4th ed)
Radiographic visualization or recording of a vein after the injection of contrast medium.
The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results.
Synthetic or natural materials, other than DRUGS, that are used to replace or repair any body TISSUES or bodily function.
Impaired conduction of cardiac impulse that can occur anywhere along the conduction pathway, such as between the SINOATRIAL NODE and the right atrium (SA block) or between atria and ventricles (AV block). Heart blocks can be classified by the duration, frequency, or completeness of conduction block. Reversibility depends on the degree of structural or functional defects.
Placement of an intravenous CATHETER in the subclavian, jugular, or other central vein.
The confinement of a patient in a hospital.
Surveillance of drugs, devices, appliances, etc., for efficacy or adverse effects, after they have been released for general sale.
Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder.

Differential effects of defibrillation on systemic and cardiac sympathetic activity. (1/1845)

OBJECTIVE: To assess the effect of defibrillation shocks on cardiac and circulating catecholamines. DESIGN: Prospective examination of myocardial catecholamine balance during dc shock by simultaneous determination of arterial and coronary sinus plasma concentrations. Internal countershocks (10-34 J) were applied in 30 patients after initiation of ventricular fibrillation for a routine implantable cardioverter defibrillator test. Another 10 patients were externally cardioverted (50-360 J) for atrial fibrillation. MAIN OUTCOME MEASURES: Transcardiac noradrenaline, adrenaline, and lactate gradients immediately after the shock. RESULTS: After internal shock, arterial noradrenaline increased from a mean (SD) of 263 (128) pg/ml at baseline to 370 (148) pg/ml (p = 0.001), while coronary sinus noradrenaline fell from 448 (292) to 363 (216) pg/ml (p = 0.01), reflecting a shift from cardiac net release to net uptake. After external shock delivery, there was a similar increase in arterial noradrenaline, from 260 (112) to 459 (200) pg/ml (p = 0.03), while coronary sinus noradrenaline remained unchanged. Systemic adrenaline increased 11-fold after external shock (p = 0.01), outlasting the threefold rise following internal shock (p = 0.001). In both groups, a negative transmyocardial adrenaline gradient at baseline decreased further, indicating enhanced myocardial uptake. Cardiac lactate production occurred after ventricular fibrillation and internal shock, but not after external cardioversion, so the neurohumoral changes resulted from the defibrillation process and not from alterations in oxidative metabolism. CONCLUSIONS: A dc shock induces marked systemic sympathoadrenal and sympathoneuronal activation, but attenuates cardiac sympathetic activity. This might promote the transient myocardial depression observed after electrical discharge to the heart.  (+info)

Mechanisms of death in the CABG Patch trial: a randomized trial of implantable cardiac defibrillator prophylaxis in patients at high risk of death after coronary artery bypass graft surgery. (2/1845)

BACKGROUND: The CABG Patch trial compared prophylactic implantable cardiac-defibrillator (ICD) implantation with no antiarrhythmic therapy in coronary bypass surgery patients who had a left ventricular ejection fraction <0.36 and an abnormal signal-averaged ECG. There were 102 deaths among the 446 ICD group patients and 96 deaths among the 454 control group patients, a hazard ratio of 1.07 (P=0.63). The mechanisms of death were classified, and hypotheses were tested about the effects of ICD therapy on arrhythmic and nonarrhythmic cardiac deaths in the CABG Patch Trial and the Multicenter Automatic Defibrillator Implantation Trial (MADIT). METHODS AND RESULTS: The 198 deaths in the trial were reviewed by an independent Events Committee and classified by the method of Hinkle and Thaler. Only 54 deaths (27%) occurred out of hospital; 145 deaths (73%) were witnessed. Seventy-nine (82%) of the 96 deaths in the control group and 76 (75%) of the 102 deaths in the ICD group were due to cardiac causes. Cumulative arrhythmic mortality at 42 months was 6.9% in the control group and 4.0% in the ICD group (P=0. 057). Cumulative nonarrhythmic cardiac mortality at 42 months was 12. 4% in the control group and 13.0% in the ICD group (P=0.275). Death due to pump failure was significantly associated with death >1 hour from the onset of symptoms, dyspnea within 7 days of death, and overt heart failure within 7 days of death. CONCLUSIONS: In the CABG Patch Trial, ICD therapy reduced arrhythmic death 45% without significant effect on nonarrhythmic deaths. Because 71% of the deaths were nonarrhythmic, total mortality was not significantly reduced.  (+info)

Atrial fibrillation detection and R-wave synchronization by Metrix implantable atrial defibrillator: implications for long-term efficacy and safety. The Metrix Investigators. (3/1845)

BACKGROUND: The long-term efficacy of atrial fibrillation (AF) detection and R-wave synchronization are critical safety requirements for the development of an implantable atrial defibrillator (IAD) for treatment of AF. METHODS AND RESULTS: The long-term efficacy of the Metrix IAD for AF detection and R-wave synchronization was tested in 51 patients. The mean duration of follow-up was 259+/-138 days (72 to 613 days). AF detection tests were performed 2240 times during observed operation with 100% specificity and 92.3% sensitivity for differentiation between sinus rhythm and AF; 2219 episodes and their electrograms stored in the device during AF detection were analyzed. The positive predictive value of the AF detection algorithm was 97.4% (lower 95% confidence limit [CL], 94.5%) in the out-of-hospital setting. A total of 242 435 R waves were analyzed for R-wave synchronization. Of these, 49% were marked for synchronized shock delivery, 82% of sinus rhythm and 36% of AF R waves, respectively. All shock markers were properly synchronized and within the R wave (overall synchronization accuracy, 100%; lower 95% CL, 99.999%). Overall, 3719 shocks have been delivered via the IAD with no instance of unsynchronized shock delivery or any episode of proarrhythmia. The observed proarrhythmic risk was 0%, with an estimated maximum proarrhythmic risk of 0.084% per shock (95% upper CL). CONCLUSIONS: The Metrix IAD can appropriately detect AF with a high specificity and sensitivity and reliably synchronize within a suitable R wave for shock delivery to minimize the risk of ventricular proarrhythmia.  (+info)

Effect of biphasic shock duration on defibrillation threshold with different electrode configurations and phase 2 capacitances: prediction by upper-limit-of-vulnerability determination. (4/1845)

BACKGROUND: The defibrillation threshold (DFT) may be affected by biphasic shock duration (BSD), electrode configuration, and capacitance. The upper limit of vulnerability (ULV) may be used to estimate the DFT. For different lead configurations and phase 2 capacitances, we investigated in 18 pigs whether the use of ULV may predict waveforms with lowest DFT. METHODS AND RESULTS: -DFT and ULV were determined by up-down protocols for 10 BSDs. ULVs were measured by T-wave scanning during ventricular pacing (cycle length 500 ms). In protocol 1 (n=6), a pectoral "active can" was combined with an electrode in the superior vena cava as common cathode and a right ventricle electrode as anode (AC+SVC). In protocol 2 and protocol 3 (n=6 each), only the "active can" was used as proximal electrode (AC). Capacitance was 150 microF during both phases in protocol 1 and protocol 3 but 150 microF (phase 1) and 300 microF (phase 2) in protocol 2. ULV and DFT demonstrated a linear correlation in each protocol (r=0.78 to 0.84). Lowest DFTs were found at 10 ms for AC+SVC and at 14 ms for AC (P<0.001). At optimal BSDs, voltage DFTs did not differ significantly between AC (527+/-57 V) and AC+SVC (520+/-70 V). Switching capacitors for phase 2 in a way that reduced leading-edge voltage by 50% while doubling capacity did not change BSD for optimal voltage DFT but increased minimum DFT from 527+/-57 V to 653+/-133 V (P=0.04). CONCLUSIONS: The BSD with lowest DFT is shorter for AC+SVC than for AC. There is no significant difference in voltage DFT between both at optimal BSD. A lower phase 2 capacitance reduces DFTs irrespective of BSD. Because strength-duration curves for DFT and ULV correlate for different BSDs, lead systems, and phase 2 capacitances, ULV determination may allow the prediction of waveforms with lowest DFT.  (+info)

Design and results of the antiarrhythmics vs implantable defibrillators (AVID) registry. The AVID Investigators. (5/1845)

BACKGROUND: The Antiarrhythmics Versus Implantable Defibrillators (AVID) Study compared treatment with implantable cardioverter-defibrillators versus antiarrhythmic drugs in patients with life-threatening ventricular arrhythmias (VAs). AVID maintained a Registry on all patients, randomized or not, with any VA or unexplained syncope who could be considered for either of the treatment strategies. Trial-eligible arrhythmias were the categories of VF cardiac arrest, Syncopal VT, and Symptomatic VT, below. METHODS AND RESULTS: Of 5989 patients screened, 4595 were registered and 1016 were randomized. Mortality follow-up through 1996 was obtained on the 4219 Registry patients enrolled before 1997 through the National Death Index. Crude mortality rates (mean+/-SD, follow-up, 16.9+/-11.5 months) were: VF cardiac arrest, 17.0% (n=1399, 238 deaths); Syncopal VT, 21.2% (n=598, 127 deaths); Symptomatic VT, 15.8% (n=1065, 168 deaths); Stable (asymptomatic) VT, 19.7% (n=497, 98 deaths); VT/VF with transient/correctable cause, 17.8% (n=270, 48 deaths); and Unexplained syncope, 12.3% (n=390, 48 deaths). CONCLUSIONS: Patients with seemingly lower-risk or unknown-risk VAs (asymptomatic VT, and VT/VF associated with a transient factor) have a (high) mortality similar to that of higher-risk, AVID-eligible VAs. The similar (and poor) prognosis of most patients with VT/VF suggests the need for reevaluation of a priori risk grouping and raises the question of the appropriate arrhythmia therapy for a broad range of patients.  (+info)

The circadian pattern of the development of ventricular fibrillation in patients with Brugada syndrome. (6/1845)

AIMS: Brugada syndrome is considered to be a distinctive subgroup of idiopathic ventricular fibrillation. Identification of the circadian pattern of ventricular fibrillation would contribute to the elucidation of its underlying pathophysiology, but this pattern remains unknown in patients with Brugada syndrome. METHODS: and Results A total of 12 consecutive Brugada syndrome patients (46+/-14 years, all male) who underwent implantation of an implantable cardioverter defibrillator were studied. The distribution of the time of ventricular fibrillation detection was examined and classified into four 6-hour time periods of the day. The mean follow-up period following implantation was 777+/-535 days. In six out of the 12 patients, ventricular fibrillation occurred during follow-up. The data logs revealed that ventricular fibrillation was detected 30 times (range, 3-9). Ventricular fibrillation was observed more frequently at night ( 1800 h to 0600 h) than in the day (0600 h to 1800 h) (93.3% [28/30] vs 6.7%[2/30], P<0.001), and during sleep than while awake (86.7% [26/30] vs 13.3%[4/30], P<0.001). Ventricular fibrillation occurred most frequently between midnight and 0600 h in patients with ventricular fibrillation episodes during sleep (76.9% [20/26] vs 23.1%[6/26], P<0.01). CONCLUSION: These results suggest that increased nocturnal vagal activity and withdrawal sympathetic activity may play an important role in the arrhythmogenesis of the Brugada syndrome.  (+info)

Inappropriate shocks delivered by implantable cardiac defibrillators during oversensing of activity of diaphagmatic muscle. (7/1845)

Two cases are reported (both men, one 72 and one 54 years old) of inappropriate shocks delivered by an implantable cardiac defibrillator (ICD) device, which oversensed the myopotentials induced by deep breathing and Valsalva manoeuvre. No damage to leads was associated with the oversensing of myopotentials. The mechanism of the inappropriate shocks was determined using real time electrograms. Modification of the duration of ventricular detection and decrease in sensitivity made it possible to avoid the oversensing of myopotentials and to deliver ICD treatment.  (+info)

Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. (8/1845)

OBJECTIVES: The aim of this study was to evaluate the survival of patients with hypertrophic cardiomyopathy (HCM) after resuscitated ventricular fibrillation or syncopal sustained ventricular tachycardia (VT/VF) when treated with low dose amiodarone or implantable cardioverter defibrillators (ICDs). BACKGROUND: Prospective data on clinical outcome in patients with HCM who survive a cardiac arrest are limited, but studies conducted before the widespread use of amiodarone and/or ICD therapy suggest that over a third die within seven years from sudden cardiac death or progressive heart failure. METHODS: Sixteen HCM patients with a history of VT/VF (nine male, age at VT/VF 19 +/- 8 years [range 10 to 36]) were studied. Syncopal sustained ventricular tachycardia/ventricular fibrillation occurred during or immediately after exertion in eight patients and was the initial presentation in eight. One patient had disabling neurologic deficit after VT/VF. Before VT/VF, two patients had angina, four had syncope and six had a family history of premature sudden cardiac death. After VT/VF all patients were in New York Heart Association class I or II, three had nonsustained VT during ambulatory electrocardiography and 11 had an abnormal exercise blood pressure response. After VT/VF eight patients were treated with low dose amiodarone and six received an ICD. Prophylactic therapy was declined by two patients. RESULTS: Mean follow-up was 6.1 +/- 4.0 years (range 0.5 to 14.5). Cumulative survival (death or ICD discharge) for the entire cohort was 59% at five years (95% confidence interval: 33% to 84%). Thirteen (81%) patients were alive at last follow-up. Two patients died suddenly while taking low dose amiodarone, and one died due to neurologic complications of his initial cardiac arrest. Three patients had one or more appropriate ICD discharges during follow-up; the times to first shock after ICD implantation were 23, 197 and 1,124 days. CONCLUSIONS: This study shows that patients with HCM who survive an episode of VT/VF remain at risk for a recurrent event. Implantable cardioverter defibrillator therapy appears to offer the best potential benefit regarding outcome.  (+info)

TY - JOUR. T1 - The impact of implantable cardioverter-defibrillator implantation on health-related quality of life in the DANISH trial. AU - Bundgaard, Johan S. AU - Thune, Jens J. AU - Nielsen, Jens C. AU - Videbæk, Regitze. AU - Haarbo, Jens. AU - Bruun, Niels E. AU - Videbæk, Lars. AU - Aagaard, David. AU - Korup, Eva. AU - Jensen, Gunnar. AU - Hildebrandt, Per. AU - Steffensen, Flemming H. AU - Eiskjær, Hans. AU - Brandes, Axel. AU - Thøgersen, Anna M. AU - Melchior, Thomas M. AU - Pedersen, Ole D. AU - Gustafsson, Finn. AU - Egstrup, Kenneth. AU - Hassager, Christian. AU - Svendsen, Jesper H. AU - Høfsten, Dan E. AU - Torp-Pedersen, Christian. AU - Pedersen, Susanne S. AU - Pehrson, Steen. AU - Køber, Lars. AU - Mogensen, Ulrik M. N1 - Published on behalf of the European Society of Cardiology. All rights reserved. � The Author(s) 2019. For permissions, please email: [email protected] PY - 2019/6/1. Y1 - 2019/6/1. N2 - AIM: The Danish Study to Assess the Efficacy of ...
The latest Implantable Cardioverter Defibrillator market research report is a compilation of the latest growth trends and the emerging market segments. The report adeptly draws readers attention to the ever-changing patterns of the Implantable Cardioverter Defibrillator industry and its prominent facets, infrastructural properties, and highly dynamic environment. The report lists down some critically important parameters that help the market bolster its global foothold and contribute substantially to future revenue generation. Our team of experts has included specific details related to the Implantable Cardioverter Defibrillator industry, such as product offerings, sales and revenue estimates, leading regions, key market contenders, and technological upgradation in the report.. The global Implantable Cardioverter Defibrillator (ICD) market size is expected to reach USD 8.81 Billion at a steady CAGR of 2.7% in 2028, according to latest analysis by Emergen Research. The market for implantable ...
William S Weintraub Emory University May 2, 2005 Cost Effectiveness of Therapy With Abnormal LV Function Post-MI Dr. Al-Khatib and colleagues are to be commended for their evaluation of the cost-effectiveness of implantable cardioverter defibrillators (ICD) based on the Multicenter Automatic Defibrillator Implantation Trial-II (MADIT-II).1 At 20 months, mortality was 14.2% in the ICD group and 19.8% in the controls, an absolute difference of 5.6%.2 Cost in the ICD group was estimated at $131,490 and in the medical therapy group $40,661, a difference of $90,829, and a gain in life years of 1.8 years.(1) The authors find ICDs to be marginally cost-effective, with a base-case estimate of the incremental cost-effectiveness ratio (ICER) of $50,500 per life-year gained. Sensitivity analysis suggested that the ICER could vary greatly, from a somewhat lower to a great deal higher value, depending on the assumptions made. The ICER was especially sensitive to the effectiveness of the ICD. The MADIT-II ...
Cardioverter-defibrillator implantation after myocardial infarction (costs for program #175169) ✔ Max Grundig Clinic ✔ Department of Cardiology and Cardiovascular Diseases ✔ BookingHealth.com
Semantic Scholar extracted view of Suppression of implantable cardioverter defibrillator therapy during magnetic resonance imaging. by Jan Nemec
Background of the study: The use of implantable cardioverter defibrillators (ICDs) is an established therapy for the prevention of death from ventricular arrhythmia. Recently a new subcutaneous ICD has been introduced, eliminating the need for transvenous lead placement in or on the heart which is mandatory in the transvenous ICD. The new subcutaneous ICD therapy already proved to be feasible and safe and is an approved therapy in Europe. It is likely that the eliminated need for transvenous lead placement substantially reduces the implantation related complications and elongates lead longevity and thus reduces inappropriate shocks associated with lead fractures. On the other hand it is unclear whether the lack of capability to provide antitachy-pacing (ATP) in the subcutaneous ICD may be a limitation for patients with frequent recurrent ventricular tachycardia. This randomized controlled trial will outline the advantages and disadvantages of the subcutaneous ICD.. Objectives of the study: (1) ...
CIDS is the fourth reported randomized controlled trial that compared ICDs with antiarrhythmic drugs in recent years. The other 3 studies were the AVID (Antiarrhythmics versus Implantable Defibrillators) trial (1), the MADIT (Multicenter Automatic Defibrillator Implantation Trial) (2), and the CASH (Cardiac Arrest Study Hamburg) trial (3). CIDS allocated 600 patients to either ICD or amiodarone therapy. The current economic analysis limited itself to the first 430 patients. CIDS showed a small, statistically nonsignificant mortality advantage for patients in the ICD group, but the cost-benefit analysis showed a very high cost per year-of-life saved by ICDs. The authors concluded that ICD implantation was not cost-effective in these patients. Several points should be made about this study relative to its predecessors. First, the patient populations in these trials have been different. For example, the CIDS patients had resuscitated VF, VT, or unmonitored syncope, whereas the CASH patients had all ...
Introduction: Implantable cardioverter defibrillators (ICDs) are indicated for primary and secondary sudden cardiac death (SCD) prevention in patients with systolic heart failure (HF). Most ICDs are never used; it is not known whether subjects who have never had an appropriate ICD shock after several years are at decreased SCD risk.. Method: Data was collected on 384 subjects enrolled between March 2002 and November 2004 from one site of the Genetic Risk Assessment of Defibrillator Events (GRADE) study, a prospective observational study of subjects with severe systolic dysfunction (EF , 30%) and ICDs. The incidence of the first appropriate ICD shock for VT or VF and of death/transplant/VAD (DTV) was calculated for years 1 to 6.. Results: The cohort was 62±12 yrs old, 78% male, 95% white, 76% ischemic, EF 20±6 %, NYHA class 2.3±0.6, median f/u 43 months. 110 (29%) subjects reached the primary endpoint of appropriate ICD shock, and 186 (48%) reached the combined endpoint of DTV. The incidence ...
Article, see p 1772. Early randomized clinical trials of primary prevention implantable cardioverter defibrillators (ICDs) in patients with nonischemic cardiomyopathy failed to establish survival benefit from this therapy; however, those trials were too small to provide definitive results.1,2 When the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial) was published in 2005, it was practice changing. SCD-HeFT showed that primary prevention ICDs significantly improve the survival of patients with a left ventricular ejection fraction ≤35% attributable to ischemic or nonischemic cardiomyopathy and New York Heart Association class II or III heart failure symptoms despite optimal medical therapy.3 Patients with nonischemic cardiomyopathy constituted about half of the 2521 total enrolled patients in SCD-HeFT.3 The results of SCD-HeFT formed the basis of a class I guideline recommendation for primary prevention ICDs in patients with New York Heart Association class II or III heart failure symptoms ...
TY - JOUR. T1 - Predictors of electrocardiographic screening failure for the subcutaneous implantable cardioverter-defibrillator in children. T2 - A prospective multicenter study. AU - Campbell, Matthew. AU - Moore, Jeremy P.. AU - Sreeram, Narayanswami. AU - von Alvensleben, Johannes C.. AU - Shah, Anjan. AU - Batra, Anjan. AU - Law, Ian. AU - Sanatani, Shubhayan. AU - Thomas, Vincent. AU - Nik-Ahd, Farnoosh. AU - Williams, Stephen. AU - Nosavan, Nina. AU - Maldonado, Jennifer. AU - Hart, Amelia. AU - Nguyen, Thuan. AU - Balaji, Seshadri. PY - 2018/5/1. Y1 - 2018/5/1. N2 - Background: Subcutaneous implantable cardioverter-defibrillator (SICD) shows promise for select patients at risk of sudden cardiac death. However, patients need to pass an electrocardiographic (ECG) screening (ECG-S) test before they can receive an SICD. Predictors of ECG-S failure in children are unclear. Objective: The purpose of this study was to identify the incidence and predictive factors for failure of ECG-S in ...
Fingerprint Dive into the research topics of Percutaneous pacemaker or implantable cardioverter-defibrillator lead removal in an attempt to improve symptomatic tricuspid regurgitation. Together they form a unique fingerprint. ...
|p|​The subcutaneous implantable cardioverter defibrillator monitors cardiac rhythm and delivers defibrillation therapy without requiring access to the heart or the vasculature. Intended benefits include preserving venous access, avoiding the risks associated with the placement and removal of transvenous leads, and simplifying the implanting procedure.|/p|
Evidence-based recommendations on subcutaneous implantable cardioverter defibrillator insertion for preventing sudden cardiac death
Its not the years in your life that count. Its the life in your years. Abraham Lincoln. Implantable cardioverter defibrillators (ICDs) have one fundamental function the prevention of sudden unexpected arrhythmic cardiac death.. As Americans age and more baby boomers become eligible for a primary prevention ICD, it is important to ensure that treatments are appropriately and effectively applied to this growing segment of the population. Yet, enrollment of patients older than age 65 years in major primary prevention ICD trials is limited. A surprising 28% of Americans suitable for an ICD by conventional criteria are over age 79 years.1 Over 40% of primary prevention ICDs in the United States are placed in patients ≥70 years old. A review of over 115,000 Medicare patients in the National Cardiovascular Database ICD Registry revealed a mean age of 75 years at the time of ICD implantation, a trend that did not change between 2006 and 2010.2,9 Implantation rates are similar in other ...
Implantable cardioverter defibrillators (ICDs) are battery-powered devices that deliver an electrical shock to restore normal sinus rhythm. Read about Implantable Cardioverter Defibrillators
Cardiology: Heart failure | Cardioverter -defibrillator implantation. Treatment in Eschweiler, Germany ✈ Find the best medical programs at BookingHealth - ✔Compare the prices ✔Online booking.
Learn more about Automatic Cardioverter Defibrillator Implantation at Doctors Hospital of Augusta DefinitionReasons for ProcedurePossible ComplicationsWhat to ExpectCall...
Understand the usages of Automatic Cardioverter Defibrillator Implantation in various health conditions. Explore other smart treatment options, see research evidence, and find out about peoples experiences with many popular treatments, including feedback from patients and professionals.
Evidence-based recommendations on implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy (CRT) for arrhythmias and heart failure
Since October 2013, our team has implanted 17 S-ICDs in 17 patients, with follow-up for at least 1 month. For both the 3-incision and the 2-incision techniques, implantation was guided by anatomical landmarks, and fluoroscopy was not used in any procedure. The first 5 implantations were performed with the 3-incision technique. Subsequently, the 2-incision technique was selected as the first-line approach, with the option to revert to the 3-incision technique if difficulties were encountered in achieving a satisfactory implant. For the 2-incision technique, the insertion tool supplied with the S-ICD system was used in combination with an 11 Fr peel-away sheath of the type commonly used for transvenous lead placement.3 After the device-pocket and xyphoid incisions were made, the sheath was mounted over the insertion tool and the combined structure was tunneled parasternally. The insertion tool was then removed, leaving the peel-away sheath in place, and the electrode was introduced into the ...
Cameron Health out of San Clemente, California has seen its Subcutaneous Implantable Defibrillator (S-ICD®) System trialed in hospitals around the worl
One embodiment of the present invention provides an implantable cardioverter-defibrillator for subcutaneous positioning over a patients ribcage, the implantable cardioverter-defibrillator including a housing, wherein the housing conforms to the patients ribcage when subcutaneously positioned; an electrode disposed upon a portion of the housing; and an electrical circuit located within the housing, wherein the electrical circuit is electrically coupled to the electrode.
Abstract: Recent studies report surprisingly low rates of implantable cardioverter defibrillator (ICD) placement for primary prevention against sudden cardiac death among patients with heart failure and left ventricular systolic dysfunction. Reasons for the low rates of utilization are not well understood. The authors examined ICD implantation rates at a university-based tertiary care center and used multivariable analysis to identify independent factors associated with ICD utilization. The ICD implantation rate for 850 eligible patients was 70%. Forty-seven (18%) patients refused implantation; women were twice as likely to refuse compared to men (8% vs 4%, P=.013). Race was not associated with utilization. On multivariable analysis, independent predictors of implantation included having a heart failure specialist (odds ratio [OR], 8.13; P,.001) or general cardiologist (OR, 2.23; P=.13) managing care, age range 70 to 79 (OR, 0.55; P,.001) or 80 and older (OR, 0.26; P,.001), female sex (OR, 0.49; ...
OBJECTIVE--To evaluate an implantable tiered therapy defibrillator system that delivered antitachycardia pacing treatment for slower well tolerated ventricular tachycardias and cardioversion or defibrillation for fast tachycardias or ventricular fibrillation. METHODS--A tiered treatment device (Ventritex Cadence V-100) was implanted in 30 patients with ventricular tachycardia that was refractory to drugs. Efficacy was evaluated by the responses of induced or spontaneous arrhythmias to the treatments delivered. RESULTS--Antitachycardia pacing successfully terminated 80% of episodes of ventricular tachycardia induced by non-invasive programmed stimulation, but acceleration was brought about by pacing in six patients in 10% of episodes. During a follow up of two to 17 (mean seven) months, 18 patients (60%) had recurrence of ventricular arrhythmias. Antitachycardia pacing terminated ventricular tachycardia in 17 of 18 patients in 87% of episodes. Twelve patients received shocks for ventricular ...
Syncope is a very common clinical problem. Given the extensive differential diagnosis, we have developed a structured approach for the evaluation and management of patients with unexplained syncope. Patients with overt cardiac, neurologic, or metabolic disturbances are identified and treated accordingly. However, the remaining patients with high-risk characteristics are hospitalized for risk stratification. After excluding patients who can benefit from pacemaker or implantable cardioverter-defibrillator implantation, an implantable loop recorder (ILR) appears to be a very effective diagnostic tool. The recent availability of a small ILR that can be implanted within minutes and provides daily data wirelessly for over 3 years appears to have elevated the ILR over short-term external electrocardiography (ECG) monitoring techniques in patients with unexplained syncope. Herein, using specific case examples, we review how we use a structural pathway at our institution to guide the evaluation and ...
Cardiovascular implantable electronic devices include pacemakers and cardioverter-defibrillators. Remote monitoring systems provide physicians with information from the implantable cardiac devices with little time delay.
We report the development of severe life threatening polymorphic ventricular tachycardia in a young woman shortly following her first pregnancy, who ultimately required the insertion of an automatic implantable cardioverter/defibrillator because of the failure of conventional antiarrhythmic therapy. Although only about 7 patients have received units in the UK to date, the experience in the USA, where up to 300 per month may be implanted, suggests that they will become a more common method of treatment in cases of life threatening arrhythmias.. ...
In this systematic review of the literature, the authors investigate the presence of psychiatric comorbidities and quality of life in patients with an implantable cardioverter defibrillator. Research shows that there are prominent signs and symptoms of anxiety and depression in patients with the implantable device.
An automatic implantable cardioverter defibrillator (AICD or ICD), continuously monitors your heart for any irregular heart rhythms (arrhythmias).
Abstract: The implantable cardioverter defibrillator (ICD) is often used in treatment and prevention of lethal cardiac arrhythmias in at-risk patients. Despite its established effectiveness, ICD therapy is associated with ongoing physical, emotional, and psychosocial distress that can impact patients quality of life (QoL). For many patients living with chronic illness, religiosity may be central to dealing with the physical and psychosocial challenges they encounter. It is hypothesized that ICD patients who are more religious will demonstrate improved QoL. To date, there are no studies that have examined the influence of religiosity on general and disease-specific QoL in the ICD population. The purpose of this study was to investigate the relationship between religiosity and QoL in ICD patients. Select variables (demographic, clinical, ICD specific, psychosocial, and religiosity) of the ICD population were explored to determine predictors of general (physical and mental health) and ...
An implantable cardioverter defibrillator (ICD) is a small battery-powered device placed in your chest to constantly monitor your heart rhythm
The use of pacemakers and implantable cardioverter defibrillator (ICD) has increased sharply over the past decade [ 1 ]. This increase has led to …
Overview of Pacemakers and Implantable Cardioverter Defibrillators (ICDs) in Children What is an implanted pacemaker? An implanted pacemaker is a small device that is implanted under the skin and sends electrical signals to start or regulate a slow heartbeat. An implanted pacemaker may be used to stimulate the heartbeat if the hearts natural pacemaker (the sinoatrial, or SA, node) is not functioning properly, has developed an abnormally slow heart rate or rhythm, or if the electrical pathways are block...
A method of manufacturing a capacitor for use in an implantable cardiac defibrillator by forming a set of conductive sheets with the same profile having a sacrificial portion. An alignment figure is formed in each sheet, and the sheets are stacked and aligned by registering the alignment figures with each other. The sacrificial portions are removed from each of the sheets, which are secured together and positioned in a capacitor housing. Each sheet may include two major portions joined by the sacrificial portion, so that each major portion may become part of a separate capacitor stack after the sacrificial portion is removed, doubling manufacturing throughput.
Background: Although crucial, research on nurses knowledge on the use of implantable cardioverter defibrillators (ICDs) is scant. The aims of the study were to investigate (i) the level of nurses knowledge on care of patients with ICDs, (ii) whether knowledge level is related to education and type of hospital where nurses practice and (iii) whether knowledge level changes among nurses over time.. Methods: We developed a questionnaire comprising 27 items in four parts: (1) Sociodemographics, (2) Technical facts about ICDs, (3) Daily life challenges and (4) Self-evaluation of knowledge. After validation, surveys were conducted during 1-week cardiac educational courses in 2003-2010. In total, 463 nurses working in cardiology-related areas participated, yielding a response rate of 91%.. Results: Practical and technical knowledge about ICDs was lacking. Nurses were unaware or did not know that mobile phones can affect the device (80%), that patients are restricted from driving heavy vehicles (69%), ...
Bryan Heart is first in the region to treat patients who suffer from sudden cardiac arrest with an implantable cardioverter defibrillator (ICD).
Ventricular Fibrillation is a disorganized electrical excitation of the heart that results in inadequate blood flow to the body. It usually ends in death within a minute. A common way to treat the symptoms of fibrillation is to implant a medical device, known as an Implantable Cardioverter Defibrillator (ICD), in the patients body. Model-based verification can supply rigorous proofs of safety and efficacy. In this paper, we build a hybrid system model of the human heart+ICD closed loop, and show it to be a STORMED system, a class of o-minimal hybrid systems that admit finite bisimulations. In general, it may not be possible to compute the bisimulation. We show that approximate reachability can yield a finite simulation for STORMED systems, and that certain compositions respect the STORMED property. The results of this paper are theoretical and motivate the creation of concrete model checking procedures for STORMED systems.
Get answers to questions about implantable cardioverter defibrillators (ICDs), including how they work and why a doctor might offer one as part of treatment.
We read with interest the study by Tapanainen et al. (1). The researchers introduced the brain natriuretic peptide (BNP) as a good predictor of sudden cardiac death (SCD) after acute myocardial infarction (AMI). In their study, BNP level of the patients with AMI was used to predict SCD. The incidence of SCD after the mean follow-up of 43 ± 13 months was 3.1%. The mean BNP level in patients with SCD was 54.4 ± 76.1 pmol/l and it was 26.1 ± 28.0 pmol/l in survivors. They found that a BNP level of 23.0 pmol/l was the best cut-off point to predict SCD. In another new study by Wang et al. (2), higher BNP was also associated with increased risk of overall death. The investigators reported a 27% increase in the risk of death with each increment of 1 SD in log of BNP level.. We know from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) investigators that the survival of postmyocardial infarction patients with ejection fraction (EF) ,30% will improve with prophylactic ...
There is only sparse data in the literature concerning the incidence of electrical storm in ICD populations as defined in the present study. Most of these data stem from patient samples evaluated in the late 1980s or early 1990s, implying that most of these patients had been treated with thoracotomy ICD devices. For instance, ODonoghue and co-workers (9)reported on 130 ICD recipients of whom 12 (9%) showed at least one episode of electrical storm defined as 10 or more appropriate ICD discharges during a 48-h period. More recently, a preliminary report (10)demonstrated an incidence of 23% (35/149 patients) of cases of electrical storm; although not specified in the paper, it can be assumed that many of those patients had received modern nonthoracotomy ICD devices. These numbers are in excellent agreement with the present finding of a 10% incidence of electrical storm in patients exclusively treated with modern nonthoracotomy ICDs.. Another important question relates to the precise time of ...
An implantable cardioverter defibrillator (ICD) is a sophisticated device that is inserted by cardiologists in patients with life-threatening heart rhythm disorders (usually ventricular tachycardia or ventricular fibrillation) to lower the risk of sudden death. Several large studies have conclusively shown that some patients with severe heart failure who have not yet experienced a life-threatening ventricular arrhythmia may also benefit from insertion of an implantable cardioverter defibrillator (ICD) to lower the chance of dying suddenly. The device continually monitors the patients heart rhythm and, if it detects a dangerous one, can either deliver a small series of electrical impulses (called anti-tachycardia pacing) or an internal electrical shock to restore normal rhythm. ICDs are inserted in a similar way to pacemakers and can also provide back-up pacing to the heart if the heart rate is too slow.. ...
A new implantable defibrillator accurately detects abnormal heart rhythms and shocks the heart back into normal rhythm, yet has no wires touching the heart, new research shows. The device, called a subcutaneous implantable cardiac defibrillator (S-ICD), is placed under the patients skin and has a wire under the skin along the left side of the breast bone. The device detects life-threatening arrhythmias from normal rhythms, and once it notices the life-threatening rhythm it will automatically shock the heart back to its normal rhythm, said lead researcher Dr. Martin Burke, director of the Heart Rhythm Center at the University of Chicago. The advantage of the device is its durability - it lasts longer because there is not as much flexibility in the wiring, Burke said. Wires in standard implantable defibrillators need to be flexible to pass through blood vessels to the heart. This makes the system enticing for younger patients who have risk of cardiac arrest who currently dont get standard ...
Paper Survival with Cardiac-Resynchronization Therapy in Mild Heart Failure Presenter MD Summary BACKGROUND The Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchro-nization Therapy (MADIT-CRT) showed that early intervention with cardiac-resyn-chronization therapy with a defibrillator (CRT-D) in patients with an electrocardio-graphic pattern showing left bundle-branch block was associated with a significant reduction in heart-failure events over…
Results 900 patients (87% men, mean age 64±10 years) were included in the analysis. During a median follow-up of 669 days (IQR 363-1322 days), 150 patients (17%) died and 191 (21%) patients received appropriate device therapy. 114 (13%) patients died without prior appropriate therapy. Stratification of the risk for death without prior appropriate therapy resulted in risk categorisation of patients as low, intermediate or high risk. NYHA ≥III, advanced age, diabetes mellitus, left ventricular ejection fraction ≤25% and a history of smoking were significant independent predictors of death without appropriate ICD therapy. 5-year cumulative incidence for death without prior appropriate therapy ranged from 10% (95% CI 6% to 16%) in low-risk patients to 41% (95% CI 33% to 51%) in high-risk patients. ...
A detachable power supply for supplying power from an external power source to a portable defibrillator for charging a battery of the portable defibrillator and operating the portable defibrillator includes a housing shaped to attach to the portable defibrillator and a latch connected to the housing for mechanically attaching the power supply to the defibrillator so that the power supply and the defibrillator form a portable, integral unit. The power supply also includes an electrical connector connected to the housing to supply power from the power supply to the defibrillator, the connector is located so that it engages a mating electrical connector on the defibrillator as the latch is engaged to connect the power supply to the defibrillator, an external power connection for bringing external power into the power supply, and a power module installed within the housing, the power module having a power circuit that converts power from the external power source to a form useable by the defibrillator, the
Transvenous pacemaker or implantable cardio-verter defibrillator (ICD) implantation procedures are usually performed under local anesthetic, and prilocaine is the most common agent to be used. The data regarding methemoglobinemia after cardiac device implantation are scarce. Thus, presently described is the case of a 47-year-old female patient with arrhythmogenic right ventricular cardiomyopathy/dysplasia who underwent ICD implantation for secondary prophylaxis and developed cyanosis as a result of prilocaine-associated methemoglobinemia. Prilocaine was administered during the procedure. To our knowledge, this is the second case in the literature presenting methemoglobinemia due to local anesthetic after transvenous cardiac device implantation. ...
Cardiac Resynchronization Therapy (CRT) has emerged as a promising therapeutic addition in patients with drug refractory heart failure (HF). Along with providing relief of symptoms of HF, cardiac resynchronization therapy defibrillators (CRT-D) are used for the prevention of sudden cardiac death (SCD). Although there are concerns that the defibrillation threshold (DFT) estimates are elevated in the heart failure (HF) patient population due to lower LV ejection fraction (EF) and left ventricular (LV) dysfunction, there is paucity of data available to evaluate this theory.. Recently, two different studies in a retrospective manner evaluated the energy requirements in patients receiving cardiac resynchronization therapy defibrillators (CRT-D). Burke et al analyzed DFTs in 50 patients each implanted with a cardiac resynchronization therapy defibrillators (CRT-D) device and an implantable cardioverter defibrillator (ICD). Although the ejection fraction (EF) in cardiac resynchronization therapy ...
TY - JOUR. T1 - Effect of Angiotensin-Converting Enzyme Inhibitors and Receptor Blockers on Appropriate Implantable Cardiac Defibrillator Shock in Patients With Severe Systolic Heart Failure (from the GRADE Multicenter Study). AU - AlJaroudi, Wael A.. AU - Refaat, Marwan M.. AU - Habib, Robert H.. AU - Al-Shaar, Laila. AU - Singh, Madhurmeet. AU - Gutmann, Rebecca. AU - Bloom, Heather L.. AU - Dudley, Samuel C.. AU - Ellinor, Patrick T.. AU - Saba, Samir F.. AU - Shalaby, Alaa A.. AU - Weiss, Raul. AU - McNamara, Dennis M.. AU - Halder, Indrani. AU - London, Barry. N1 - Publisher Copyright: © 2015 Elsevier Inc. Copyright: Copyright 2017 Elsevier B.V., All rights reserved.. PY - 2015/4/1. Y1 - 2015/4/1. N2 - Sudden cardiac death (SCD) is a leading cause of mortality in patients with cardiomyopathy. Although angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) decrease cardiac mortality in these cohorts, their role in preventing SCD has not been well ...
Two recent studies in the Journal of the American College of Cardiology (JACC) look at findings from the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy) Study. New data from MADIT-CRT study identifies who are the super-responders, and a second paper finds a possible new effect of statins. The first study looked at predictors of left ventricular ejection fraction (LVEF) super-response to cardiac resynchronization therapy with defibrillator (CRT-D) and whether super-response translated into improved, event-free survival in patients with mildly symptomatic heart failure (HF). Currently, few data exist on predictors of super-response to CRT-D and associated morbidity and mortality in mildly symptomatic HF populations. Based on the findings from the study, researchers concluded that six baseline factors predict LVEF super-response in CRT-D-treated patients with mild HF. These factors are: female sex, no prior myocardial infarction, QRS ...
TY - JOUR. T1 - Pulmonary embolism in patients with transvenous cardiac implantable electronic device leads. AU - Noheria, Amit. AU - Ponamgi, Shiva P.. AU - DeSimone, Christopher V.. AU - Vaidya, Vaibhav R.. AU - Aakre, Christopher A.. AU - Ebrille, Elisa. AU - Hu, Tiffany. AU - Hodge, David O.. AU - Slusser, Joshua P.. AU - Ammash, Naser M.. AU - Bruce, Charles J. AU - Rabinstein, Alejandro. AU - Friedman, Paul Andrew. AU - Asirvatham, Samuel J. PY - 2016/2/1. Y1 - 2016/2/1. N2 - Background Cardiac implantable electronic devices (CIEDs) are commonly associated with transvenous lead-related thrombi that can cause pulmonary embolism (PE). Methods and results We retrospectively evaluated all patients with transvenous CIED leads implanted at Mayo Clinic Rochester between 1 January 2000, and 25 October 2010. Pulmonary embolism outcomes during follow-up were screened using diagnosis codes and confirmed with imaging study reports. Of 5646 CIED patients (age 67.3 ± 16.3 years, 64% men, mean follow-up ...
Looking for online definition of Cardiac defibrillator in the Medical Dictionary? Cardiac defibrillator explanation free. What is Cardiac defibrillator? Meaning of Cardiac defibrillator medical term. What does Cardiac defibrillator mean?
An implantable cardioverter defibrillator is a surgically implanted electronic device to treat rapid heart rhythms. Learn more about ICDs here at Ohio State.
Definition : Implantable cardiac pacemaker and/or defibrillator/cardiac pacemakers leads used for sensing cardiac bioelectric signals and delivering electrical stimuli to synchronize ventricular contractions. These leads are connected to implantable cardiac pacemakers or defibrillator/cardioverter/pacemakers for resynchronization therapy in patients with advanced heart failure (e.g., dilated cardiomyopathy) and/or serious heart-rhythm problems such as delayed ventricular activation and contraction (i.e., ventricular dysynchrony).. Entry Terms : Biventricular Pacemaker/Implantable Cardioverter Defibrillators (Bi-V/ICDs) , Biventricular Pacemakers , Cardiac Resynchronization Therapy Leads , Ventricular Resynchronization Leads , Resynchronization Cardiac Rhythm Leads , Cardiac Resynchronization Therapy Defibrillator (CRT-D) Systems , Biventricular Pacing Devices , Defibrillation Electrodes , Electrodes, Defibrillation. UMDC code : 20377 ...
Heart Failure clinical trial. Clinical trial for CarDiac MagnEtic Resonance for Primary Prevention Implantable CardioVerter DebrillAtor ThErapy: an International Registry (DERIVATE).
Study Objective: To assess the efficacy of the automatic implantable cardioverter-defibrillator in preventing sudden death in high-risk patients.. Design: Nonrandomized cohort study.. Setting: A university teaching hospital with 500 beds.. Patients: Consecutive sample of 78 patients with symptomatic, sustained ventricular tachyarrhythmias that were previously drug-refractory.. Interventions: Before February 1985, patients received treatment with the defibrillator and amiodarone if they presented with loss of consciousness (group A) and amiodarone alone if they did not lose consciousness (group C). After February 1985, because the availability of the defibrillator was severely curtailed, patients who lost consciousness received treatment with amiodarone alone (group B).. Measurements and Main Results: The risk for recurrent arrhythmias was similar between groups. The actuarial risk for sudden death in group B was 31% (95% confidence interval, 11% to 51%) at 1 and 2 years, a value that was ...
APPROVAL FOR A MODIFICATION TO THE INDICATIONS FOR USE FOR THE COGNIS CRT-D MODELS N118, N119; LIVIANCRT-D MODELS H220, H225, H227 AND H229; AND CONTAK RENEWAL 3 RF HE CRT-D MODELSH210, H215, H217, H219 CARDIAC RESYNCHRONIZATION THERAPY DEFIBRILLATORS (CRT-DS) AS FOLLOWS:THESE BOSTON SCIENTIFIC CARDIAC RESYNCHRONIZATION THERAPY DEFIBRILLATORS (CRT-DS) ARE INDICATED FOR PATIENTS WITH HEART FAILURE WHO RECEIVE STABLE OPTIMAL PHARMACOLOGIC THERAPY (OPT) FOR HEART FAILURE AND WHO MEET ANY ONE OF THE FOLLOWING CLASSIFICATIONS:1) MODERATE TO SEVERE HEART FAILURE (NYHA CLASS III-IV) WITH EF = 120 MS; OR2) LEFT BUNDLE BRANCH BLOCK (LBBB) WITH QRS >= 130 MS, EF
The DYNAGEN X4 CRT-D features 17 pacing vector options designed to resolve phrenic nerve stimulation and high thresholds. It brings forward the same long lasting battery technology as previous generations of Boston Scientific devices.
Implantable atrial defibrillators are able to deliver shocks immediately after the onset of paroxysmal atrial fibrillation (PAF). It is anticipated that rapid restoration of sinus rhythm may allow electrical remodeling and thus reduce PAF recurrence (sinus rhythm begets sinus rhythm). Methods: 8 patients with atrial defibrillators (Metrix 3020, InControl) were studied for a mean of 11.6+/-3.7 (range 8-18) months. Data were prospectively collected by device telemetry and patient diary. Patient characteristics, PAF episodes and results of device therapy were recorded. Results: All patients had failed |2 medical therapies. 6/8 patients had structurally normal hearts, 2/8 had dilated left atria and hypertension. Mean number of PAF episodes per month prior to implant was 3.0 (range 0.25-8.0). Post-implant, patients had a mean of 15.4+/-9 (range 0-28) AF episodes during follow-up, with 12.6+/-10.8 attempted therapies with a success rate of 74%. The most common cause of failure of therapy was early
A large observational study published in JAMA suggests that patients with left bundle-branch block (LBBB) and longer QRS duration derive the most benefit from a cardiac resynchronization therapy defibrillator (CRT-D). The findings appear to support current, but often criticized, guidelines from the American College of Cardiology, American Heart Association, and the Heart Rhythm Society, in which a class I […]. ...
TY - JOUR. T1 - Axillo-iliac artery bypass for recurrent aortic coarctation to reduce cardiac afterload. AU - Yamashita, Yoshiyuki. AU - Tatewaki, Hideki. AU - Matsumoto, Takashi. AU - Shiose, Akira. PY - 2018/10/1. Y1 - 2018/10/1. N2 - A 13-year-old girl, who had undergone interrupted aortic arch repair with an 8-mm graft as a neonate and Fontan completion in childhood, developed ventricular fibrillation due to long-QT syndrome. Cardioverter defibrillator implantation was planned. Preoperative catheterization showed a 45-mmHg aortic pressure gradient and ventricular end-diastolic pressure of 11 mmHg. This indicated that recurrent coarctation had adversely affected ventricular function. After consideration of the patients age, symptoms and anatomical/surgical complexities, axillo-iliac bypass with cardioverter defibrillator implantation was performed. Postoperative ventricular end-diastolic pressure was 6 mmHg. Axillo-iliac bypass is a surgical option for coarctation that can reduce cardiac ...
0018] In some embodiments, the frictional force between the rotation member and the implantable device causes the implantable device to rotate at a speed corresponding to the specified rotation speed of the rotation member. The frictional force between at least a portion of the outer surface of the rotation member and at least a portion of the inner surface of the implantable device, in further embodiments, is due to the build up of kinetic energy between at least a portion of the outer surface of the rotation member and at least a portion of the inner surface of the implantable device when the rotation member is rotated relative to the implantable device. In still further embodiments, the frictional force between at least a portion of the outer surface of the rotation member and at least a portion of the inner surface of the implantable device is due to the build up of kinetic energy between at least a portion of the outer surface of the rotation member, at least a portion of the inner surface ...
The primary objective is to assess the 18-month incidence of shocks in subjects implanted with the EMBLEM Subcutaneous Implantable Defibrillator (S-ICD) programmed with zone cutoffs at 200 bpm and 250 bmp and: - an indication for implantation of a defibrillator for primary prevention of sudden cardiac death; - a left ventricular ejection fraction ≤ 35%. The 18-month incidence rate will be compared to an Objective Performance Criteria derived from transvenous ICDs programmed to minimize shocks in the MADIT RIT study. The secondary objective is to assess perioperative complications. Device and procedure related complications at 6 months and implant success rate at 3 months will be assessed to fulfill Post Market Clinical Follow-up (PMCF) requirements.. ...
Medtronic Sprint Fidelis Defibrillator leads - Find trial lawyers and attorneys with experience in lawsuits involving Medtronic Sprint Fidelis Defibrillator leads. Contact an attorney who can help yo
A 36-year-old man underwent partial left ventriculectomy (PLV) to treat end-stage dilated hypertrophic cardiomyopathy. Mitral valve replacement and tricuspid valve annuloplasty were performed to correct the mitral and tricuspid valve insufficiency. The patient suffered ventricular tachycardia and ventricular fibrillation (VT/VF) soon after surgery, but antiarrhythmic-drug therapy was sufficiently effective to treat the VT/VF. On the third postoperative day, an implantable cardioverter-defibrillator (ICD) was implanted to prevent these arrhythmias. Two months later after his discharge from the hospital, recurrent VT/VF appeared and was supposedly associated with renal failure. Continuous hemodialysis was efficacious to ameliorate the systemic circulation, and ventricular arrhythmias disappeared. He survived due to 18 ICD shocks. In appropriately selected patients, ICDs have been recognized as one of the cost-effective therapeutic options. ICDs might be recommended for patients in the ...
ABUD, Atilio M. et al. Retrospective Analysis of Patients with Brugada Syndrome and Implantable Cardioverter Defibrillator. Rev. argent. cardiol. [online]. 2014, vol.82, n.1, pp.21-25. ISSN 1850-3748.. Introduction The Brugada syndrome is an inherited, electrical anomaly, with increased risk of sudden cardiac death. Automatic cardioverter defibrillators are the only effective treatment to prevent sudden cardiac death, while therapy management in asymptomatic patients is still controversial. Objectives The aims of the study were to evaluate the incidence and causes of appropriate and inappropriate shocks and the complications related to the device, and to identify the relation of clinical and electrophysiological study variables with the incidence of appropriate shocks. Methods This was a single-center, retrospective registry of patients with Brugada syndrome, with type-1 electrocardiographic pattern, either spontaneous or induced by ajmaline infusion, who were recipients of automatic implantable ...
The ALTITUDE clinical science program is analyzing comprehensive data from the LATITUDE® Patient Management system to provide insight into meaningful questions related to implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) therapy ...
RnRMarketResearch.com adds report BRIC Cardiac Rhythm Management Market Outlook to 2020 to its store.. BRIC Cardiac Rhythm Management Market Outlook to 2020″, provides key market data on the BRIC Cardiac Rhythm Management Devices market. The report provides value, in millions of US dollars, and volume (in units) and average price data (in US dollars), within market categories Cardiac Resynchronisation Therapy (Defibrillators and Pacemakers), Implantable Cardioverter Defibrillators, Implantable Loop Recorders and Pacemakers.. The report also provides company shares and distribution shares data for the market category, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Cardiac Rhythm Management Market wherever available.. Inquire For Discount @ http://www.rnrmarketresearch.com/contacts/discount?rname=180874 .. The data in the report is derived from dynamic market forecast models. GlobalData uses epidemiology and capital ...
Guides you through decision to get an implantable cardioverter defibrillator (ICD). Gives information about ICDs and asks questions to help you learn if an ICD is right for you. Covers benefits and risks. Includes an interactive tool to help you decide.
A large observational study published in JAMA suggests that patients with left bundle-branch block (LBBB) and longer QRS duration derive the most benefit from a cardiac resynchronization therapy defibrillator (CRT-D). The findings appear to support current, but often criticized, guidelines from the American College of Cardiology, American Heart Association, and the Heart Rhythm Society, in which a class I recommendation…. Click here to continue reading…. ...
We report a case of a patient with idiopathic dilated cardiomyopathy and recurrent ventricular tachycardias refractory to antiarrhythmic treatment with amiodarone. A cardioverter defibrillator implantation was performed by the transvenous technique,
A case of a 51 year old patient with a history of myocardial infarction (MI) and recurrent ventricular tachycardia (VT) is presented. Three months after MI the patient underwent coronary angioplasty and one year later received prophylactic implantable cardioverter-defibrillator (ICD) due to complex ventricular arrhythmias, detected on Holter ECG monitoring, and depressed left ventricular ejection fraction. Later on the patient started to experience palpitations and ICD shocks during physical activity (cycling). Interrogation of the ICD memory showed appropriate shocks due to slow (160 betas/min) VT. The device was reprogrammed and new antitachycardia pacing (ATP) algorithms were enabled, however, it occurred proarrhythmic due to the ATP-induced acceleration of VT rate. Finally, in April 2005 he received 37 appropriate ICD shocks during a few hours. The patient was selected for RF ablation and underwent successful procedure with the use of the electro-anatomical CARTO mapping system ...
Typically, cellular phones do not affect the functioning of pacemakers or ICDs. Most devices made today have a filter that allows the use of the majority of cellular phones used throughout the world, including analog and digital technologies. However, new frequencies are being made available for cellular phones by the Federal Communications Commission, and these new frequencies may make pacemakers or ICDs less reliable. Studies are being done to investigate this further. General recommendations include keeping a cell phone at least six inches away from a pacemaker or ICD and to avoid carrying a cell phone in a breast pocket over the device.. Make sure your child uses caution when going through security detectors at airports and government buildings, such as courthouses. Although it is generally safe to go through airport security detectors (they should not damage the pacemaker or ICD), inform airport security personnel that your child has a pacemaker or ICD before he or she goes through ...
Typically, cellular phones do not affect the functioning of pacemakers or ICDs. Most devices made today have a filter that allows the use of the majority of cellular phones used throughout the world, including analog and digital technologies. However, new frequencies are being made available for cellular phones by the Federal Communications Commission, and these new frequencies may make pacemakers or ICDs less reliable. Studies are being done to investigate this further. General recommendations include keeping a cell phone at least six inches away from a pacemaker or ICD and to avoid carrying a cell phone in a breast pocket over the device.. Make sure your child uses caution when going through security detectors at airports and government buildings, such as courthouses. Although it is generally safe to go through airport security detectors (they should not damage the pacemaker or ICD), inform airport security personnel that your child has a pacemaker or ICD before he or she goes through ...
BACKGROUND:Cardiac device infection (CDI) is a serious complication of cardiovascular implantable electronic device (CIED) implantations. Many risk factors have been identified, but several are still uncertain. This study aimed to identify and evaluate the risk factors. Moreover, an infection control protocol (ICP) was carried out, and its efficacy in reducing CDIs was investigated. MATERIAL AND METHODS:A total of 1259 patients who received permanent pacemaker (PPM) implantations were enrolled in this study in a 3-year period in a high-volume center and low-volume centers in the central area of Shaanxi Province, China. Follow-up data of all enrolled patients were collected. The risk factors for CDIs were identified and analyzed. The ICP was adopted in the low-volume centers. Data, including CDI rates, medical costs, and microbiology, were collected and compared. RESULTS:Male gender, diabetes, CKD, operation duration, PPM replacement, and low center volume were identified as the risk factors for CDIs.
Dear Members,. We did it! On Tuesday 4th September a defibrillator and oxygen resuscitation kit was delivered and installed at the club as well as the initial training of the first 8 club members in the use of this life saving equipment. The storage cabinet for the defibrillator is located in the library on the wall above the refrigerator. The oxygen resuscitation case is orange in colour and stored in close proximity.. Thank you to everyone who contributed and made this purchase possible, but we still welcome donations into the fund from those members yet to support the project. This will allow for the long term upkeep and maintenance of this equipment as well as facilitating additional first aid training of club members.. It is my earnest hope that the defibrillator will never require to be used, but in such an event wish to ensure that, as far as possible, the defibrillator is not used on a person who does not wish it to be used on them. To that end and should you NOT wish the defibrillator ...
China Defibrillator suppliers directory and China Defibrillator products catalog, providing Defibrillator trade leads among China factory, manufacturers, suppliers, and global buyers from free business guide of China
A cardiac device that stores physiological sensor data from multiple sensors is provided. A patient may use a portable triggering device to cause the cardiac device to store the data when the patient experiences symptoms that appear to be due to an abnormal heart condition. Alternatively, the data may be stored when the cardiac device identifies an abnormal physiological condition. A physician may select which sensors are used to store the data and may also adjust the number of memory buffers in which the data is to be stored.
Implantable defibrillator[edit]. In people felt to be at higher risk of sudden cardiac death, an implantable cardioverter- ... Rickard J, Wilkoff BL (2016). "Advances in implantable cardioverter defibrillator therapy". Expert Review of Cardiovascular ... Those at higher risk of sudden cardiac death may be treated using an implantable cardioverter defibrillator (ICD).[4] In those ... "Implantable cardioverter-defibrillator harm in young patients with inherited arrhythmia syndromes: A systematic review and meta ...
... implantable cardiac defibrillators (ICDs); insulin pumps; diagnostics, including sepsis; fibroid embolisation; pain management ...
2005). "Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure". N Engl J Med. 352 (3): 225-37. ... 2004). "Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure". N ... "Cost-effectiveness of implantable cardioverter-defibrillators". N. Engl. J. Med. 353 (14): 1471-80. doi:10.1056/NEJMsa051989. ... may also benefit from an implantable cardioverter-defibrillator (ICD), a device that is proven to reduce all-cause mortality by ...
i) Implantable Cardioverter-Defibrillator. *Initial Capabilities Document. *International Classification of Diseases. *ICE - (i ...
Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study". ... An implantable cardiac defibrillator may be placed to reduce the chance of death from recurrence. In the United States, ... Shun-Shin MJ, Zheng SL, Cole GD, Howard JP, Whinnett ZI, Francis DP (June 2017). "Implantable cardioverter defibrillators for ... An implantable cardioverter defibrillator (ICD) is a battery-powered device that monitors electrical activity in the heart and ...
Automatic Implantable Cardioverter Defibrillator (AICD)[edit]. The AICD was an implantable defibrillator that served as a ... An implantable defibrillator is a device implanted under the skin through an incision in the shoulder. Leads from the implanted ... The automatic implantable cardioverter defibrillator is the size of a deck of cards and weighs nine ounces. Although these ... The first AICD was five times larger and three times heavier than Guidant's latest implantable defibrillators. In the 1980s, ...
He had an implantable cardioverter-defibrillator (ICD) implemented afterwards. He has a wife, Marcella, and two sons, Ruben and ...
Implantable cardioverter-defibrillator Mangrum, J. Michael; DiMarco, John P. (2000-03-09). "The Evaluation and Management of ... using a manual or automatic defibrillator, though some newer defibrillators can do both, and pads and an electrical stimulus to ... In addition to synchronized transcutaneous pacing offered by newer cardiac monitor/defibrillators, there is also an option for ... Other forms of cardiac pacing are transvenous pacing, epicardial pacing, and permanent pacing with an implantable pacemaker. ...
Implantable cardioverter-defibrillator (ICD). *Transcutaneous pacing. *Automated external defibrillator. *Cardiopulmonary ... Implantable loop recorder. Cardiac stress test Bruce protocol. Electrophysiology study. Cardiac imaging. Angiocardiography. ... by cables to a machine which has the combined functions of an ECG display screen and the electrical function of a defibrillator ... "Part 6: electrical therapies: automated external defibrillators, defibrillation, cardioversion, and pacing: 2010 American ...
Stewart now has an implantable cardioverter-defibrillator in his chest. Stewart married actress Alexa Davalos on May 19, 2019. ...
As a cardiologist Khaykin specializes in the implantation of pacemakers, implantable cardioverter-defibrillator (ICDs), cardiac ... January 2014). "Higher Mortality Risk Among Patients With Delayed Follow-Up After Implantable Cardioverter Defibrillator ... June 2013). "Survival after implantable cardioverter-defibrillator implantation in the elderly" (PDF). Circulation. 127 (24): ... Implantable cardioverter-defibrillator registry, Ontario's version of the National Cardiovascular Data Registry. ...
The privately held company's focus was on a new generation of minimally invasive implantable cardioverter-defibrillator (ICD) ... May 2010). "An Entirely Subcutaneous Implantable Cardioverter-Defibrillator" (PDF). N. Engl. J. Med. New England Journal of ... which they called a Subcutaneous Implantable Defibrillator (S-ICD). Cameron Health's approach avoided implanting transvenous ... Meier, Barry (13 May 2010). "Under-Skin Defibrillators Seen Closer to Reality". The New York Times. Stiles, Steve (December 4, ...
A specific type of pacemaker called a defibrillator combines pacemaker and defibrillator functions in a single implantable ... "MP3 Headphones Interfere With Implantable Defibrillators, Pacemakers - Beth Israel Deaconess Medical Center". www.bidmc.org. ... Detecting and Distinguishing Cardiac Pacing Artifacts Implantable Cardioverter Defibrillator from National Heart, Lung and ... Sometimes devices resembling pacemakers, called implantable cardioverter-defibrillators (ICDs) are implanted. These devices are ...
Later hackers demonstrated remote control of insulin pumps and implantable cardioverter defibrillators. Poorly secured Internet ...
An implantable cardiac defibrillator may be recommended in those with certain types of irregular heartbeat. Surgery, in the ... July 2007). "Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy". ... an implantable cardioverter-defibrillator (ICD) or a combination pacemaker/ICD all-in-one unit may be recommended as an ...
Implantable defibrillators are used to treat serious life-threatening rapid heart rhythms. These devices monitor the heart, and ... Implantable defibrillators are most commonly used in patients with heart failure, cardiomyopathies, or inherited arrhythmia ... Cardiac devices in the form of pacemakers or implantable defibrillators may also be required to treat arrhythmias. Pacemakers, ... These devices are frequently combined with a defibrillator. In very severe cases of heart failure, a small pump called a ...
... the first implantable cardioverter defibrillator or ICD, the first wearable defibrillator or LifeVest defibrillator, and heart ... Hauser, RG (December 2009). "Development and Industrialization of the Implantable Cardioverter-Defibrillator: A Personal and ... developed the world's first implantable cardioverter defibrillator or ICD. Heilman was born on Christmas Day, 1933 in Tarentum ... Heilman made the initial human automatic implantable defibrillator. In 2002, based on an ICD invention, Heilman, Langer, ...
Technologies such as an implantable cardioverter defibrillator, artificial ventilation, ventricular assist devices, and ... Old age and the implantable cardioverter defibrillator in US health care". Social Science & Medicine. 72 (1): 6-14. doi:10.1016 ...
... is a concept also applicable to internal or implantable cardiac defibrillators. The test needed to ... doi:10.1016/j.jacc.2008.05.016; Defibrillation Threshold Testing in Implantable Cardioverter-Defibrillators Might Less Be More ... The highest amount of energy that an external defibrillator can deliver at the present time is 360 joules biphasic. In clinical ... Typical examples are the minimum amount of energy, expressed in joules, delivered by external defibrillator paddles or pads, ...
In severe cases an implantable cardiac defibrillator or heart transplant may be recommended. In 2013, about 1.5 million cases ...
The only proven way to prevent SADS is with an implantable cardioverter-defibrillator. Oral antiarrhythmics such as propranolol ... 2003). "Defibrillator Versus beta-Blockers for Unexplained Death in Thailand (DEBUT): a randomized clinical trial". Circulation ...
A specific type of pacemaker called a defibrillator combines pacemaker and defibrillator functions in a single implantable ... Implantable Cardioverter Defibrillator from National Heart, Lung and Blood Institute. *Current indications for CRT-P and CRT-D ... "MP3 Headphones Interfere With Implantable Defibrillators, Pacemakers - Beth Israel Deaconess Medical Center". www.bidmc.org. ... Sometimes devices resembling pacemakers, called implantable cardioverter-defibrillators (ICDs) are implanted. These devices are ...
In January 2020, while at Levante UD he had an implantable cardioverter-defibrillator (ICD) implanted through surgery, which ... He, however, continued after having implemented an implantable cardioverter-defibrillator (ICD) in January 2020. On 20 August ...
"Machines in Our Hearts: The Cardiac Pacemaker, the Implantable Defibrillator, and American Health Care". Google Books. Fiedler ...
In June 2013, it was reported that he had an implantable cardioverter-defibrillator fitted. His tour was cancelled in July 2013 ...
He is known for his role in developing the world's first implantable cardiac defibrillator. Born and raised in Hyderabad, India ... He joined Intec Systems in 1980 and developed IP key to the development of the automatic implantable defibrillator, a device ... He then spent three years At Rutgers Medical School before deciding to leave and work on the first implantable cardioverter- ... defibrillator with Intec Systems. Imran attributes his pursuit of innovation to being inspired by an experience he had as a ...
Takeuchi has been primarily recognized and awarded for her innovation regarding implantable cardiac defibrillators. Millions of ... for inventing the silver vanadium oxide battery that powers implantable cardiac defibrillators Inductee, National Inventors ...
One effective form of arrhythmia termination in individuals with LQTS is placement of an implantable cardioverter-defibrillator ... In these patients, primary prevention with use of implantable cardioverter-defibrillators can be considered. Potassium ... or an implantable cardiac defibrillator. For people with LQTS who survive cardiac arrest and remain untreated, the risk of ...
1992 Gershman, A., Reznik, G.: Implantable Cardioverter Defibrillator Lead Systems: Current and Future Directions. Cardio. 1992 ... 1992 Gershman, A., Reznik, G.: Percutaneous Endoscopic Implantation of Automatic Implantable Cardioverter/Defibrillator (AICD ... The Epicardial Surface And Its Application In The Percutaneous Implantation Of Automatic Implantable Cardioverter/Defibrillator ...
A study in 2014 found that the iPad 2 could cause electromagnetic interference (EMI) in implantable cardioverter defibrillators ... "iPad2 Use in Patients With Implantable Cardioverter Defibrillators Causes Electromagnetic Interference: The EMIT Study". ... Maintain at least 6 inches (approximately 15 cm) of separation between your pacemaker or defibrillator and iPad, the iPad Smart ... "Myth killer: iPad magnet effect on defibrillators wasn't "discovered" by a 14-year-old". Engadget. May 10, 2013. Retrieved July ...
Active implantable medical devices (AIMD). High CanadaEdit. The Medical Devices Bureau of Health Canada recognizes four classes ... Medical devices such as pacemakers, insulin pumps, operating room monitors, defibrillators, and surgical instruments, including ... Camara, Carmen; Peris-Lopez, Pedro; Tapiador, Juan E. (June 2015). "Security and privacy issues in implantable medical devices ... EN 45502-1 which is for Active implantable medical devices, and IEC 62304 for medical software. The US FDA also published a ...
ICD(英語:Implantable cardioverter-defibrillator)). *心電圖 (ECG/EKG). *骨內給藥 (IO) ...
Implantable Cardioverter Defibrillator from National Heart, Lung and Blood Institute. *Current indications for CRT-P and CRT-D ... Some combine a pacemaker and defibrillator in a single implantable device. Others have multiple electrodes stimulating ... "MP3 Headphones Interfere With Implantable Defibrillators, Pacemakers - Beth Israel Deaconess Medical Center". www.bidmc.org. ... Sometimes devices resembling pacemakers, called implantable cardioverter-defibrillators (ICDs) are implanted. These devices are ...
... field include antiarrhythmic drug therapy and surgical implantation of pacemakers and implantable cardioverter-defibrillators. ... Surgical procedures: pacemaker and defibrillator implantation and follow upEdit. *Implantation of single and dual chamber ... Implantation of "biventricular" pacemakers and defibrillators for patients with congestive heart failure ...
Implantable cardioverter-defibrillator. ReferencesEdit. *^ a b BBC News:'Button battery' warning over child deaths in ...
Halperin, Daniel (2008). Pacemakers and Implantable Cardiac Defibrillators: Software Radio Attacks and Zero-Power Defenses (PDF ... "MP3 Headphones Interfere With Implantable Defibrillators, Pacemakers - Beth Israel Deaconess Medical Center". www.bidmc.org. ... "Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure". N. Engl. J. Med. 352 (3): 225-37. doi: ... the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial". JAMA. 288 (24): 3115-23. doi:10.1001/jama.288.24.3115. PMID ...
2006). "Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: ... supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a ...
CRT defibrillators (CRT-D) also incorporate the additional function of an implantable cardioverter-defibrillator (ICD), to ... Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure - National ... "Cardiac Resynchronization Therapy and Implantable Cardioverter Defibrillator Therapy in Advanced Heart Failure". Heart Failure ... Chest radiographs of cardiac resynchronization therapy with defibrillator (CRT-D) in an individual with dilated cardiomyopathy ...
Implantable loop recorder. Cardiac stress test Bruce protocol. Electrophysiology study. Cardiac imaging. Angiocardiography. ... Hardy used a defibrillator to shock the heart to restart beating. This heart did beat in Rush's chest for 60 to 90 minutes ( ...
Advance care planning should note if a patient is using a implantable cardioverter-defibrillator (ICD) and give instructions ...
Implantable cardiac defibrillator, calcium channel blockers, amiodarone[2]. Treatment. Procainamide, cardioversion, ... An implantable cardiac defibrillator or medications such as calcium channel blockers or amiodarone may be used to prevent ... or internally to the heart by an implantable cardioverter-defibrillator (ICD) if one has previously been inserted. ... 360J with a monophasic defibrillator, or 200J with a biphasic defibrillator) unsynchronised cardioversion (defibrillation).[13] ...
Local anesthesia is also used during insertion of IV devices, such as pacemakers and implantable defibrillators, ports used for ...
... field include antiarrhythmic drug therapy and implantation of pacemakers and automatic implantable cardioverter-defibrillators ...
There is inconclusive data regarding the use of pacemakers and implantable cardioverter defibrillators as useful treatments for ...
An implantable cardiac defibrillator may be placed to reduce the chance of death from recurrence.[79] ... Bernard Lown (born 1921), original developer of the defibrillator. *Woldemar Mobitz (1889-1951), described and classified the ... field include antiarrhythmic drug therapy and implantation of pacemakers and automatic implantable cardioverter-defibrillators ...
A chest film after insertion of an implantable cardioverter-defibrillator, showing the shock generator in the upper left chest ...
Automated external defibrillator (AED). References[edit]. *^ a b Atkins DL, Berger S, Duff JP, Gonzales JC, Hunt EA, Joyner BL ... Implantable loop recorder. Cardiac stress test Bruce protocol. Electrophysiology study. Cardiac imaging. Angiocardiography. ... This study only counted heart rhythms which can respond to defibrillator shocks (tachycardia).[69] A major reason for the ...
Implantable loop recorder. Cardiac stress test Bruce protocol. Electrophysiology study. Cardiac imaging. Angiocardiography. ... Biotelemetry of patients for any of the above reasons and such monitoring can include internal and external defibrillators and ...
... having been fitted with an implantable cardioverter-defibrillator (ICD).[29] Muamba attended Bolton's home match against ... Bolton's club doctor later confirmed that Muamba had received numerous defibrillator shocks both on the pitch and in the ...
Medications, implantable cardiac defibrillator, heart transplant[1][2]. Medication. ACE inhibitors, beta blockers, diuretics, ... In severe cases an implantable cardiac defibrillator or heart transplant may be recommended.[1][2] ...
Some implants are bioactive, such as subcutaneous drug delivery devices in the form of implantable pills or drug-eluting stents ... his more than 50 years of contributions that have spawned innovations ranging from burn treatments to miniature defibrillators ... implantable pacemaker pulse generators and endosseous (intra-bone) implants. ...
... an implanted device such as a pacemaker or an implantable cardiac defibrillator may be recommended.[4] In some moderate or ... treatment with an automatic implantable cardioverter defibrillator (AICD) is indicated to reduce the risk of severe life- ... insertion of an implantable cardioverter-defibrillator or cardiac resynchronization therapy. Echocardiography can also help ...
The only proven way to prevent SADS is by implantation of a implantable cardioverter-defibrillator. Oral antiarrhythmics such ... 2003). "Defibrillator Versus beta-Blockers for Unexplained Death in Thailand (DEBUT): a randomized clinical trial". Circulation ...
Examples include the artificial heart, artificial heart valve, implantable cardioverter-defibrillator, cardiac pacemaker, and ... Some implants are bioactive, such as subcutaneous drug delivery devices in the form of implantable pills or drug-eluting stents ... In United Kingdom, Prof Derek Alderson, president of the Royal College of Surgeons, concludes: "All implantable devices should ... Examples include the LINX, implantable gastric stimulator, diaphragmatic/phrenic nerve stimulator, neurostimulator, surgical ...
In people who may be at risk of serious arrhythmias, drug therapy or an implantable cardioverter-defibrillator (ICD) may be ... Left ventricular assist device: (LVAD): This implantable mechanical pump helps a weak heart pump. LVADs are often implanted ...
... implantable cardioverter defibrillators and cardiac resynchronization devices) ...
Many patients with implantable cardioverter-defibrillators fail to meet criteria for use. A study published in JAMA Tuesday ... Implantable Cardioverter-Defibrillators Overused 1 in 5 with implantable cardioverter-defibrillator dont meet criteria for use ... life-saving devices known as implantable cardioverter-defibrillators, or ICDs, may be getting them unnecessarily, according to ... "The big challenge is that we get a snapshot of patients who received defibrillators, but we dont get to know anything in this ...
Remote monitoring of implantable cardioverter defibrillators: prospective analysis. Pacing Clin Electrophysiol. 2004;27:757-63. ... Ramsdale D.R., Rao A. (2012) Implantable Cardioverter Defibrillators. In: Cardiac Pacing and Device Therapy. Springer, London. ...
Health Information on Pacemakers and Implantable Defibrillators: MedlinePlus Multiple Languages Collection ... Pacemakers and Implantable Defibrillators: MedlinePlus Health Topic - English Marcapasos y desfibrilador implantable: Tema de ...
Implantable cardioverter defibrillators account for one-third of the decrease in cardiac arrests caused by ventricular ...
Implantable cardioverter-defibrillators (ICDs) are small battery-powered devices that can deliver a small electric shock to the ... A study published this week in JAMA indicates that about 1 in 5 patients who have an implantable cardioverter-defibrillators ( ...
An implantable cardioverter-defibrillator (ICD) is a device that detects any life-threatening, rapid heartbeat. This abnormal ... Pacemakers and implantable cardioverter-defibrillators. In: Zipes DP, Libby P, Bonow RO, Mann DL, Tomaselli GF, Braunwald E, ... An implantable cardioverter-defibrillator (ICD) is a device that detects any life-threatening, rapid heartbeat. This abnormal ... Assessment of implantable devices. In: Roberts JR, Custalow CB, Thomsen TW, eds. Roberts and Hedges Clinical Procedures in ...
Cardioverter/defibrillator replacement, Implantable cardioverter-defibrillator (ICD) insertion, ICD lead extraction, Cardiac ... Implantable cardioverter defibrillator knowledge and end-of-life device deactivation: A cross-sectional survey. Palliative ... Efficacy and safety of the subcutaneous implantable cardioverter defibrillator: A systematic review. Heart. 2017;103:1315. ... Sports and driving with an implantable cardioverter-defibrillator. Cardiology in Review. 2017;25:36. ...
An implantable cardioverter-defibrillator (ICD) or automated implantable cardioverter defibrillator (AICD) is a device ... Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005 Jan 20; 352(3):225-37 ... Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352:225-237 Stevenson ... Vasquez LD, Sears SF, Shea JB, Vasquez PM (2010). "Sexual health for patients with an Implantable Cardioverter Defibrillator". ...
Implantable cardioverter defibrillators (ICDs) are used to detect dangerously fast heartbeats and give a lifesaving shock to ... A different type of defibrillator may be placed along a patients left side. Like pacemakers, ICDs contain a generator ...
10 - Survival afters hock therapy in implantable cardioverter-defibrillator and cardiac resynchronisation therapy-defibrillator ... Implantable cardioverter-defibrillators shock paradox An article from the e-journal of ESC Council for Cardiology Practice Vol. ... Shock delivery by implantable cardioverter defibrillator (ICD) is a life-saving measure in ventricular tachyarrhythmia. ... 15 - Optimizing implantable cardioverter-defibrillator treatment of rapid ventricular tachycardia: antitachycardia pacing ...
... the implantable cardioverter-defibrillator including a housing, wherein the housing conforms to the patients ribcage when ... One embodiment of the present invention provides an implantable cardioverter-defibrillator for subcutaneous positioning over a ... Electrode system for implantable defibrillator. US5376104. 2 Feb 1993. 27 Dec 1994. Nihon Kohden Corporation. Defibrillator ... 1. An implantable cardioverter/defibrillator of the type including a plurality of components, the implantable cardioverter/ ...
The S-ICD System is a Subcutaneous Implantable Cardioverter Defibrillator for people who are at risk of Sudden Cardiac Arrest. ... Westerman, Stacy B; El-Chami, Mikhael (2018). "The subcutaneous implantable cardioverter defibrillator--review of the recent ... This could improve the time needed to get used to the implantable device, although this is subjective. The lead goes into the ... http://www.s-icd.eu http://www.bostonscientific.com/en-EU/products/defibrillators/s-icd-emblem.html http://www.sicdsystem.com/ ...
Implantable Cardioverter-Defibrillators in Tetralogy of Fallot. Paul Khairy, Louise Harris, Michael J. Landzberg, Sangeetha ... Implantable Cardioverter-Defibrillators in Tetralogy of Fallot. Paul Khairy, Louise Harris, Michael J. Landzberg, Sangeetha ... Implantable Cardioverter-Defibrillators in Tetralogy of Fallot. Paul Khairy, Louise Harris, Michael J. Landzberg, Sangeetha ...
Implantable Cardioverter Defibrillator. An Implantable Cardioverter Defibrillator is an implantable cardiac device which ... New Implantable Cardioverter Defibrillators to avoid unnecessary shocks. by Medindia Content Team on January 15, 2006 at 6:19 ... This new Implantable Cardioverter Defibrillators (ICDs), detects shock waves from the whole part of the heart by working as an ... Electrocardiogram rather than the conventional Implantable cardioverter defibrillators which detects shock waves from small ...
Protecta DR and VR Implantable Cardioverter Defibrillators. Protecta DR ICDs. 7.7 seconds BOS*. 9.2 seconds RRT†. 37 cc,‡ 68 g ... Inappropriate implantable cardioverter-defibrillator shocks in MADIT-II: frequency, mechanisms, predictors, and survival impact ... Protecta DR and VR Implantable Cardioverter Defibrillators. Protecta™ DR and VR ICDs with SmartShock Technology™ are designed ... Understanding implantable cardioverter defibrillator shocks and storms: medical and psychosocial considerations for research ...
Getting an Implantable Cardioverter Defibrillator Surgery: What to Expect - Implantable Cardioverter Defibrillators ... Implanting an implantable cardioverter defibrillator (ICD) is not an open-heart procedure. Before the surgery medication is ... Detail - A defibrillator typically is implanted in the upper chest.. *A small incision, approximately 2 inches, will be made in ...
The Subcutaneous Implantable Defibrillator. A New Technology That Raises an Existential Question for the Implantable ... Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-237. ... Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med. 2005;353:1471-1480. ... This is the fourth decade that the implantable cardioverter-defibrillator (ICD) has been in clinical use for the prevention of ...
Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against ... Implantable cardioverter defibrillators work - so why arent we using them? Message Subject (Your Name) has sent you a message ... Use of implantable cardioverter defibrillators in Canadian and US survivors of out-of-hospital cardiac arrest. CMAJ 2007;177:41 ... Thus, the implantable cardioverter defibrillator will be truly life-saving for only a small percentage of those in whom we ...
Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against ... The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator ... Implantable cardioverter-defibrillator registry risk score models for acute procedural complications or death after implantable ... Pacemakers and Implantable Cardioverter-Defibrillators Q&A What are subacute complications of implantable cardioverter- ...
An implantable automatic cardioverter defibrillator system having a subcutaneous housing, one lead and subcutaneous electrode, ... An implantable automatic defibrillation system comprising: an implantable automatic defibrillator; a pair of electrical leads ... providing an implantable automatic defibrillator, a pair of electrical leads operably connectable to the defibrillator, and a ... An implantable automatic defibrillation system comprising: an implantable automatic defibrillator having a housing comprising a ...
Care guide for Implantable Cardioverter Defibrillator. Includes: possible causes, signs and symptoms, standard treatment ... What do I need to know about implantable cardioverter defibrillator insertion?. An implantable cardioverter defibrillator (ICD ... Learn more about Implantable Cardioverter Defibrillator. Micromedex® Care Notes. *Removal Of Implantable Cardioverter ...
Heart Failure: Should I Get an Implantable Cardioverter-Defibrillator (ICD)?. Heart Problems: Should I Get an Implantable ... Should I Get an Implantable Cardioverter-Defibrillator (ICD)?. *Heart Rhythm Problems: Should I Get an Implantable Cardioverter ... Should I Get an Implantable Cardioverter-Defibrillator (ICD)?. *Heart Rhythm Problems: Should I Get an Implantable Cardioverter ... An implantable cardioverter-defibrillator (ICD) is a battery-powered device that can fix an abnormal heart rate or rhythm and ...
An implantable cardioverter-defibrillator (ICD) is a specialized device designed to directly treat a cardiac tachydysrhythmia. ... What is an implantable cardioverter-defibrillator (ICD)?. What are pacemakers and implantable cardioverter-defibrillators (ICD ... Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against ... Pacemakers and Implantable Cardioverter-Defibrillators) and Pacemakers and Implantable Cardioverter-Defibrillators What to Read ...
In a cardioverter/defibrillator system, an electrical circuit includes an energy storage device, an output circuit for ... Electrode system for implantable defibrillator. US5376104. Feb 2, 1993. Dec 27, 1994. Nihon Kohden Corporation. Defibrillator ... Current truncated waveform defibrillator. US5507781. Aug 18, 1994. Apr 16, 1996. Angeion Corporation. Implantable defibrillator ... Canister designs for implantable cardioverter-defibrillators. US6952608. Nov 5, 2001. Oct 4, 2005. Cameron Health, Inc.. ...
Despite the unquestionable mortality advantages of implantable cardioverter defibrillators [ICDs], some patients with ICDs will ... Analysis of implantable cardioverter defibrillator therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) ... Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225-37.PubMed ... Partner quality of life in the antiarrhythmics versus implantable defibrillators trial. J Cardiovasc Nurs. 2007;22:472-9.PubMed ...
... Carsten Lennerz,1 Herribert Pavaci,1 ... et al., "Transvenous extraction of implantable cardioverter-defibrillator leads under advisory-a comparison of Riata, Sprint ... and non-recalled implantable cardioverter-defibrillator leads," Heart Rhythm, vol. 10, no. 10, pp. 1444-1450, 2013. View at ... "16-Year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States: 1993 to ...
An Implantable Cardioverter Defibrillator is an implantable cardiac device which defibrillates the heart in case of life- ... CRT used along with a defibrillator is referred to as CRT-D.. How is Implantable Cardioverter Defibrillator (ICD) Implanted?. ... Implantable Cardioverter Defibrillator - Related News. Study: More Likely to Suffer from Heart Disease Are Persons With ... How Does Implantable Cardioverter Defibrillator (ICD) Work?. ICD has four main functions:. *Anti-tachycardia pacing (ATP): The ...
33271 Insertion of subcutaneous implantable defibrillator electrode. *33272 Removal of subcutaneous implantable defibrillator ... Who Should Receive the Subcutaneous Implanted Defibrillator? The Subcutaneous Implantable Cardioverter Defibrillator (ICD) ... implantable subcutaneous lead defibrillator system. *93644 Electrophysiologic evaluation of subcutaneous implantable ... The automatic implantable cardioverter defibrillator (ICD) is a device designed to monitor a patients heart rate, recognize ...
In comparison, implantable cardioverter defibrillator discharge occurred in a total of 398 patients in the 3 implantable ... I have an implantable cardioverter defibrillator (ICD), and Ive been taking fish oil supplements because I had heard of their ... The discharge of implantable cardioverter defibrillators has also been used as a surrogate marker for sudden death. Leaf and ... The implantable cardioverter defibrillator trials included in our meta-analysis involved patients with pre-existing arrhythmia ...
Buy Pacemakers and Implantable Cardioverter Defibrillators by Amin Al-Ahmad, Kenneth A. Ellenbogen from Waterstones today! ... Pacemakers and Implantable Cardioverter Defibrillators: An Experts Manual (Hardback). Amin Al-Ahmad (author), Kenneth A. ...
  • Jan. 4, 2011 -- One in five patients who receive the heart-shocking, life-saving devices known as implantable cardioverter-defibrillators, or ICDs , may be getting them unnecessarily, according to a study published in the Journal of the American Medical Association Tuesday. (go.com)
  • A study published this week in JAMA indicates that about 1 in 5 patients who have an implantable cardioverter-defibrillators (ICDs) placed were being treated against the available evidence and the prevailing guidelines. (forbes.com)
  • Implantable cardioverter-defibrillators (ICDs) are small battery-powered devices that can deliver a small electric shock to the heart in response to a life-threatening arrhythmia (when the heart starts beating rapidly and inefficiently). (forbes.com)
  • Implantable cardioverter defibrillators ( ICDs ) are used to detect dangerously fast heartbeats and give a lifesaving shock to correct the heart's rhythm. (hrsonline.org)
  • Devices that may interfere with implantable cardioverter defibrillators (ICDs). (mayoclinic.org)
  • http://www.heart.org/HEARTORG/Conditions/Arrhythmia/PreventionTreatmentofArrhythmia/Devices-that-may-Interfere-with-Implantable-Cardioverter-Defibrillators-ICDs_UCM_448464_Article.jsp. (mayoclinic.org)
  • Despite the unquestionable mortality advantages of implantable cardioverter defibrillators [ICDs], some patients with ICDs will experience psychosocial concerns after implantation, including symptoms of anxiety, depression, and post traumatic stress disorder, as well as ICD-related distress. (springer.com)
  • The purpose of the study is to see how effective a drug called ranolazine is in reducing the risk of ventricular arrhythmia and death in people with implantable cardioverter-defibrillators (ICDs). (clinicaltrials.gov)
  • The registry will obtain information to determine the safety of sports participation for patients with defibrillators (ICDs). (clinicaltrials.gov)
  • Boston Scientific won FDA approval for its EMBLEM MRI Subcutaneous Implantable Defibrillator (S-ICD), as well as retroactive magnetic resonance (MR) conditional labeling for already implanted EMBLEM S-ICDs. (medgadget.com)
  • To address this issue, the safety of serial cardiac MR scans was evaluated in patients with implantable cardioverter defibrillators (ICDs). (bmj.com)
  • The Company seeks to develop the product candidate for the treatment of ventricular tachycardia (VT) in patients with implantable cardioverter defibrillators (ICDs). (prnewswire.com)
  • Armetheon is also developing its anti-arrhythmic drug candidate, budiodarone, for the treatment of ventricular tachycardia (VT) in patients with implantable cardioverter defibrillators (ICDs). (prnewswire.com)
  • The aim of this Cochrane Review was to compare the benefits and harms of using versus not using implantable devices that restore heart rhythm (implantable cardioverter-defibrillators (ICDs)) in addition to medications in people with non-ischaemic heart disease. (cochrane.org)
  • The aim of the study was to describe experiences of hypertrophic cardiomyopathy (HCM) patients with implantable defibrillators (ICDs). (diva-portal.org)
  • Implantable cardioverter defibrillators (ICDs) are efficient in reducing mortality in patients with left ventricular systolic dysfunction. (nih.gov)
  • The FDA is aware of reports of magnetic interference between breast tissue expanders with magnetic injection ports and either implantable cardioverter-defibrillators (ICDs) or pacemakers in patients, interfering with the functioning of these cardiac devices. (fda.gov)
  • ICDs are implantable devices used to correct life-threatening heart rhythm abnormalities in patients at risk for sudden cardiac death. (fda.gov)
  • When the electrical leads of these so-called implantable cardioverter-defibrillators, or ICDs, detect an abnormal heart rhythm, the attached pager-size generator delivers a shock that restores the normal cadence. (thefreelibrary.com)
  • Background of the study: The use of implantable cardioverter defibrillators (ICDs) is an established therapy for the prevention of death from ventricular arrhythmia. (clinicaltrials.gov)
  • Inappropriate ICD Shocks and Complications in HCM IntroductionThe expanded use of implantable cardioverter-defibrillators (ICDs) to prevent sudden cardiac death (SCD) in hypertrophic cardiomyopathy (HCM) based on risk stratification in individuals without known previous ventricular arrhythmia is justified by an acceptable risk of device-related adverse events. (diva-portal.org)
  • Implantable cardioverter defi brillators (ICDs) are the most effective treatment for life-threatening ventricular arrhythmias, reducing mortality in patients at a high risk of sudden cardiac death (SCD). (srce.hr)
  • The ACC Foundation (ACCF) and Heart Rhythm Society (HRS), along with key specialty societies, on Feb. 28 released appropriate use criteria (AUC) for implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy (CRT) . (acc.org)
  • Six areas are covered within the document: ICDs for primary prevention, ICDs for secondary prevention, comorbidities, CRT devices, generator replacements with pre-existing cardiovascular implantable electronic devices, and dual- vs. single-chamber ICDs. (acc.org)
  • As implantable cardiac defibrillators (ICDs) are increasingly ubiquitous in society, it is not suprizing that their effects might be caught on television. (blogspot.com)
  • Implantable cardioverter defibrillators (ICDs) have one fundamental function the prevention of sudden unexpected arrhythmic cardiac death. (acc.org)
  • However, the FibroScan is currently contraindicated in patients with cardiac pacemakers (PM) or implantable cardioverter-defibrillators (ICD). (hindawi.com)
  • Temple Health and 6ABC-TV collaborated on a sponsored segment about cardiac devices such as pacemakers and defibrillators. (templehealth.org)
  • Dr. Joshua Cooper debunks 8 common myths about implantable heart devices like pacemakers and defibrillators. (templehealth.org)
  • 16-Year Trends in the Infection Burden for Pacemakers and Implantable Cardioverter-Defibrillators in the United States. (bostonscientific.com)
  • FDA approves first subcutaneous heart defibrillator. (medscape.com)
  • An implantable automatic cardioverter defibrillator system having a subcutaneous housing, one lead and subcutaneous electrode, the housing comprising the other electrode. (google.co.uk)
  • NICE published guidance in April 2013 on the insertion of a subcutaneous implantable defibrillator with the following guidance: Current evidence on the efficacy of the insertion of a subcutaneous implantable cardioverter defibrillator (ICD) for the prevention of sudden cardiac death in the short and medium term is adequate. (wellmark.com)
  • This objective of this study is to confirm the long-term safety and effectiveness of the subcutaneous implantable defibrillator (S-ICD) System. (bioportfolio.com)
  • This randomized controlled trial will outline the advantages and disadvantages of the subcutaneous implantable cardioverter defibrillator (ICD) compared to the transvenous ICD. (clinicaltrials.gov)
  • subcutaneous defibrillator. (ecri.org)
  • Trends and In-Hospital Outcomes Associated With Adoption of the Subcutaneous Implantable Cardioverter Defibrillator in the United States. (bostonscientific.com)
  • An Implantable Cardioverter Defibrillator is an implantable cardiac device which defibrillates the heart in case of life-threatening arrhythmias. (medindia.net)
  • Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. (medscape.com)
  • A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. (medscape.com)
  • Few medical therapies pose the issue of how to avoid sudden cardiac death as starkly as does the implantable cardioverter defibrillator - a device that is implanted like a pacemaker, which has been well established as a safe and effective means to reduce the death rate among survivors of cardiac arrest (secondary prevention) 1 - 3 and among people at risk for ventricular arrhythmias (primary prevention). (cmaj.ca)
  • Birnie and colleagues have been appropriately cautious in the interpretation of these data: not all sudden deaths are due to ventricular arrhythmias, and they acknowledge that we really don't know what the appropriate rate of defibrillator implantation should be in survivors of sudden cardiac death as a broad group. (cmaj.ca)
  • The automatic implantable cardioverter defibrillator (ICD) is a device designed to monitor a patient's heart rate, recognize ventricular fibrillation (VF) or ventricular tachycardia (VT), and deliver an electric shock to terminate these arrhythmias to reduce the risk of sudden death. (wellmark.com)
  • Evidence-based recommendations on implantable cardioverter defibrillators and cardiac resynchronisation therapy for people with ventricular arrhythmias or heart failure. (nice.org.uk)
  • This guidance replaces NICE technology appraisal guidance on implantable cardioverter defibrillators for arrhythmias (TA95) and NICE technology appraisal guidance on cardiac resynchronisation therapy for the treatment of heart failure (TA120). (nice.org.uk)
  • This means that, if a patient has increased risk of ventricular arrhythmias and/or heart failure and the doctor responsible for their care thinks that implantable cardioverter therapy or cardiac resynchronisation therapy is the right treatment, it should be available for use, in line with NICE's recommendations. (nice.org.uk)
  • A wearable defibrillator can prevent sudden death in people with dangerous heart arrhythmias, according to research presented at the American Heart Association's Scientific Sessions 2011. (medicalxpress.com)
  • Destabilizing effects of mental stress on ventricular arrhythmias in patients with implantable cardioverter-defibrillators. (springer.com)
  • The primary requirement of the implantable cardioverter defibrillator (ICD) is to preserve life by terminating life-threatening arrhythmias (VT/VF). (centerwatch.com)
  • On the third postoperative day, an implantable cardioverter-defibrillator (ICD) was implanted to prevent these arrhythmias. (umin.ac.jp)
  • An implantable cardioverter-defibrillator (ICD) or automated implantable cardioverter defibrillator (AICD) is a device implantable inside the body, able to perform cardioversion, defibrillation, and (in modern versions) pacing of the heart. (wikipedia.org)
  • 3. The implantable cardioverter/defibrillator of claim 1 , wherein the first and second structural portions and the connecting structure are configured to enable implantation in a patient such that the heart will be disposed substantially between the first and second cardioversion/defibrillation electrodes. (google.co.uk)
  • electrical lead means operably connected to the patch electrode means and operably connectable to the implantable means for automatic defibrillation for conducting an electrical pulse from the implantable means for automatic defibrillation to each patch electrode means. (google.co.uk)
  • Defibrillation can also be carried out with an external device, an Automatic External Defibrillator (AED), which helps to deliver the shock in case of Sudden Cardiac Arrest. (medindia.net)
  • This can be accredited to the development of advanced automated external defibrillators, rising cases of sudden cardiac arrest at out-of-hospital settings and increasing number of public access defibrillation programs across the globe. (prnewswire.com)
  • Among these regions, North America region dominates the overall automated external defibrillator market owing to the rising incidence of target diseases, technological advancements in defibrillators and increasing number of public defibrillation programs in the region. (prnewswire.com)
  • Implantable cardioverter defibrillator therapy reduces sudden cardiac deaths by providing antitachycardia pacing and defibrillation to stop ventricular tachycardia and fibrillation in patients with heart failure who are at risk of developing malignant ventricular tachyarrhythmias. (bmj.com)
  • Conversely, resynchronisation therapy alone reduces the risk of worsening deaths owing to heart failure as well as sudden cardiac deaths w2 suggesting that the addition of such therapy to implantable cardioverter defibrillation might further reduce the risk of death. (bmj.com)
  • The pacing energy storage is charged from residual energy from the defibrillator source to permit high energy pacing after defibrillation. (patents.com)
  • 2. The implantable defibrillator and pacer of claim 1 further including a switch, wherein said voltage regulator is coupled to said first storage means through said switch which is actuated by a fourth control signal developed by said defibrillation and pacer control logic after cardioverting energy is supplied to the lead system. (patents.com)
  • Multicenter Automatic Defibrillator Implantation Trial (MADIT) Investigators. (medscape.com)
  • In their analysis, they carefully excluded a large proportion of patients with reversible causes for their aborted sudden death, since causes such as concurrent myocardial infarction constitute the major legitimate reason to withhold cardioverter defibrillator implantation. (cmaj.ca)
  • As monopolies, provincial governments are able to tightly regulate the roll-out of a new technology, by placing caps on the volumes covered by government insurance and by other indirect disincentives for procedures such as defibrillator implantation. (cmaj.ca)
  • Implantation of a Cardioverter/Defibrillator in Subpectoral Region Combined with a Nonthoracotomy Lead System, Pace, vol. 15, Apr. (freepatentsonline.com)
  • Therefore, a single marker of high risk for sudden death may be sufficient to justify consideration for prophylactic defibrillator implantation in selected patients with HCM. (nih.gov)
  • Implantation of defibrillators has evolved dramatically since its introduction by Mirowski in 1980. (wiley.com)
  • Since the first implantation, a huge body of information on the impact of implantable cardioverter defibrillators (ICD) on prognosis has become available, first as observational studies and later as prospective randomized trials. (wiley.com)
  • The implantation of the implantable cardioverter defibrillator (ICD) takes approximately two hours. (bumrungrad.com)
  • A study called the Multicenter Automatic Defibrillator Implantation Trial (or MADIT), the results of which were first published in The New England Journal of Medicine in 1996, showed that implantation of an ICD improved survival in people with coronary heart disease who had reduced left ventricular function and ventricular tachycardia. (diabetesselfmanagement.com)
  • Will implantation of defibrillators improve survival in patients with prior myocardial infarction and severely impaired left ventricular function? (mja.com.au)
  • The cardiology community is familiar with the general details of the groundbreaking ICD trials MADIT II (Multicenter Automatic Defibrillator Implantation Trial) and SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial) are representative. (acc.org)
  • Some people with this condition will have a special device that combines a defibrillator and biventricular pacemaker placed. (medlineplus.gov)
  • The precaution regarding the use of FibroScan in subjects with cardiac pacemaker (PM) or implantable cardioverter-defibrillators (ICD) is puzzling. (hindawi.com)
  • An implantable cardioverter defibrillator (ICD) looks similar to a pacemaker, though slightly larger. (rochester.edu)
  • We tested the hypothesis that prophylactic cardiac-resynchronization therapy in the form of biventricular stimulation with a pacemaker with or without a defibrillator would reduce the risk of death and hospitalization among patients with advanced chronic heart failure and intraventricular conduction delays. (nih.gov)
  • A pacemaker reduced the risk of the secondary end point of death from any cause by 24 percent (P=0.059), and a pacemaker-defibrillator reduced the risk by 36 percent (P=0.003). (nih.gov)
  • An implantable cardioverter defibrillator (ICD) is a battery-powered device similar to a pacemaker that is placed under the skin in the chest. (brighamandwomens.org)
  • Learn more about implantable cardioverter defibrillator and pacemaker devices in our health library . (brighamandwomens.org)
  • Color-enhanced x-ray of an implantable cardioverter-defibrillator (ICD), commonly known as a pacemaker. (sciencephoto.com)
  • An implantable cardioverter defibrillator (ICD) looks very similar to a pacemaker, except that it is slightly larger. (medcentral.org)
  • An ICD is also known as an automatic implantable cardioverter-defibrillator (AICD). (healthlinkbc.ca)
  • A different type of defibrillator may be placed along a patient's left side. (hrsonline.org)
  • The defibrillator, once implanted, monitors the patient's rhythm and waits. (cmaj.ca)
  • The authors make a convincing argument that, although we are making some slow gains, these defibrillators continue to be greatly underutilized, particularly when academic centres are uninvolved in the patient's care. (cmaj.ca)
  • In a cardioverter/defibrillator system, an electrical circuit includes an energy storage device, an output circuit for controlling delivery of pulse therapy from the energy storage device to a patient, and a sensing circuit coupled across the patient to sense the patient's heart signal. (google.com)
  • Defibrillators are devices which are used to deliver therapeutic shock to a patient's heart in life-threatening conditions such as ventricular fibrillation, cardiac arrhythmia, pulseless ventricular tachycardia, among others. (prnewswire.com)
  • Lead II electrocardiogram showing Torsades being shocked by an implantable cardioverter-defibrillator back to the patient's baseline cardiac rhythm . (wikidoc.org)
  • The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. (medscape.com)
  • Quality of life in the antiarrhythmics versus implantable defibrillators. (springer.com)
  • In the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial, the device was shown to be superior to therapy with antiarrhythmic medications for reducing all causes of death in survivors of ventricular fibrillation (irregular, chaotic heart rhythm that begins in the hearts lower chambers). (bio-medicine.org)
  • Shock delivery by implantable cardioverter defibrillator (ICD) is a life-saving measure in ventricular tachyarrhythmia. (escardio.org)
  • Dr. Andrew Grace and colleagues from Papworth Hospital and University of Cambridge with collaboration from Cameron Health of San Clemente has devised new Implantable cardioverter defibrillators, which are devised to detect shock waves from the whole heart rather than part of the muscle. (medindia.net)
  • Implantable cardioverter defibrillator recipients: quality of life in recipients with and without ICD shock delivery: a prospective study. (medscape.com)
  • The Florida Shock Anxiety Scale (FSAS) for patients with implantable cardioverter defibrillators: testing factor structure, reliability, and validity of a previously established measure. (springer.com)
  • Of the two main components in the name "implantable cardioverter-defibrillator" (commonly abbreviated ICD), a cardioverter is a device that restores normal heart rhythm through an electric shock, and a defibrillator is an apparatus that uses a particularly strong electric shock to counteract the type of abnormal rhythm known as fibrillation. (diabetesselfmanagement.com)
  • The only effective therapy to avert SCD is an electrical cardioverter shock via an automated external defibrillator (AED) or with an implantable-cardioverter defibrillator (ICD) defibrillator, that has become a first-line treatment and preventive therapy for patients at risk for VT/VF. (europa.eu)
  • There is evidence that implantable cardioverter-defibrillator (ICD) for primary prevention in people with an ischaemic cardiomyopathy improves survival rate. (cochrane.org)
  • Long-term follow-up on high-rate cut-off programming for implantable cardioverter defibrillators in primary prevention patients with left ventricul. (nih.gov)
  • Long-term follow-up on high-rate cut-off programming for implantable cardioverter defibrillators in primary prevention patients with left ventricular systolic dysfunction. (nih.gov)
  • Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention. (duke.edu)
  • Current guidelines suggest the use of Implantable Cardioverter Defibrillator (ICD) in primary prevention of SCD in both New York Heart Association (NYHA) class II and class III heart failure. (scirp.org)
  • Current evidence based guidelines 3 4 5 recommend an implantable cardioverter defibrillator for the primary prevention of sudden cardiac death in selected patients with impaired left ventricular function, and cardiac resynchronisation therapy for improvement of symptoms and survival in selected patients with abnormal ventricular conduction. (bmj.com)
  • An implantable cardioverter-defibrillator (ICD) is a device that detects any life-threatening, rapid heartbeat. (medlineplus.gov)
  • An implantable cardioverter defibrillator (ICD) is a small device that monitors your heart rate and rhythm. (drugs.com)
  • An implantable cardioverter-defibrillator (ICD) is a battery-powered device that can fix an abnormal heart rate or rhythm and prevent sudden death. (healthlinkbc.ca)
  • This could improve the time needed to get used to the implantable device, although this is subjective. (wikipedia.org)
  • An implantable device which tracks the heart rhythm delivers electrical impulses and shocks the heart when it skips out of the rhythm is called an Implantable Cardioverter Defibrillator. (medindia.net)
  • An implantable cardioverter-defibrillator (ICD) is a specialized device designed to directly treat many dysrhythmias, and it is specifically designed to address ventricular tachyarrhythmias. (medscape.com)
  • However, to avoid unknown risks of potential interaction, the manufacturer has advised against the use of the device in pregnant women and in patients with active implantable medical device [ 4 ]. (hindawi.com)
  • Since its introduction, now more than 20 years ago, the implantable cardioverter-defibrillator (ICD) has evolved from a non-programmable (committed) device into a sophisticated multi-programmable, multi-functional device with extensive diagnostic and therapeutic options. (bmj.com)
  • The TriHealth Heart Institute helps patients monitor their heart issues through the use of an implantable cardioverter defibrillator (ICD), a device that detects any life-threatening, rapid heartbeat. (trihealth.com)
  • An Implantable Cardioverter Defibrillator (ICD) is a battery-powered device placed under your skin, beneath the collarbone, that is connected to your heart by one or more wires (leads) and keeps track of your heartbeat. (medmovie.com)
  • Current state-of-the-art electronics and batteries have enabled an implantable device to deliver enough energy to defibrillate the heart without the need for a lead in or on the heart. (wikidoc.org)
  • An implantable cardioverter defibrillator (ICD) is a small electronic device connected to the heart. (spectrumhealth.org)
  • And while some people die because a device fails to fire when it should--a problem that spawned massive recalls of certain models last year--many more perish because no one recognized that a defibrillator could have saved their lives. (thefreelibrary.com)
  • An implantable cardioverter defibrillator (ICD) is a small battery-powered device placed in your chest to constantly monitor your heart rhythm and immediately deliver electric shocks when life-threatening arrhythmia is discovered, usually when the lower left chamber of the heart beats abnormally fast. (bumrungrad.com)
  • Sudden death in implantable cardioverter-defibrillator recipients: Clinical context, arrhythmic events and device responses. (springer.com)
  • DALLAS, April 16 In the first study of its kind, an implantable cardioverter defibrillator (ICD), a device used to treat heart rhythm abnormalities, was found to be moderately cost-effective for preventing sudden cardiac death, according to a report in todays rapid access Circulation: Journal of the American Heart Association. (bio-medicine.org)
  • 2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction. (bostonscientific.com)
  • http://www.heart.org/HEARTORG/Conditions/Arrhythmia/PreventionTreatmentofArrhythmia/Living-With-Your-Implantable-Cardioverter-Defibrillator-ICD_UCM_448462_Article.jsp. (mayoclinic.org)
  • Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. (medscape.com)
  • We therefore performed a meta-analysis of randomized controlled trials that examined the effect of fish-oil supplementation in patients with implantable cardioverter defibrillators who are at risk of ventricular arrhythmia to determine the overall effect of fish oils. (cmaj.ca)
  • The search terms were combined into a single phrase "fish and implantable cardioverter defibrillator and arrhythmia. (cmaj.ca)
  • What are subacute complications of implantable cardioverter-defibrillator (ICD) therapy? (medscape.com)
  • Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct sudden death survivors. (medscape.com)
  • Kuck KH, Cappato R, Siebels J, Rüppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). (medscape.com)
  • So - after all these years of experience, after all the studies showing benefit, after all the guidelines recommending implantable cardioverter defibrillators as a class I indication with level A evidence - how is it that we continue to underuse this safe and effective therapy? (cmaj.ca)
  • Cadence" tiered therapy defibrillator Model V-100. (freepatentsonline.com)
  • The implantable type is expected to hold a significant market share during the next five years owing to the development of technologically advanced devices with extended longevity, rapid growth in the number of implant procedures, increasing adoption of cardiac resynchronization therapy defibrillators, among others. (prnewswire.com)
  • Evolution of guidelines for defibrillator therapy. (wiley.com)
  • Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. (nih.gov)
  • In patients with advanced heart failure and a prolonged QRS interval, cardiac-resynchronization therapy decreases the combined risk of death from any cause or first hospitalization and, when combined with an implantable defibrillator, significantly reduces mortality. (nih.gov)
  • Implantable cardioverter-defibrillator is recommended among patients with nonischemic dilated cardiomyopathy or ischemic heart disease at least 40 days following myocardial infarction (MI) with left ventricular ejection fraction (LVEF) of 35% and symptomatic heart failure on chronic guideline-directed medical therapy (GDMT) in order to prevent sudden cardiac death and decrease mortality. (wikidoc.org)
  • Objective To review the evidence base from randomised controlled trials of combined cardiac resynchronisation therapy and implantable cardioverter defibrillator therapy in left ventricular impairment and symptomatic heart failure. (bmj.com)
  • Included trials compared cardiac resynchronisation therapy, implantable cardioverter defibrillator therapy, combined resynchronisation and implantable defibrillator therapy, and medical therapy alone, in patients with impaired left ventricular systolic function. (bmj.com)
  • Combined cardiac resynchronisation and implantable cardioverter defibrillator therapy reduced the number of deaths by one third compared with medical therapy alone (odds ratio 0.57, 95% credible interval 0.40 to 0.80) but did not further improve survival when compared with implantable defibrillator therapy (0.82, 0.57 to 1.18) or resynchronisation (0.85, 0.60 to 1.22) therapy alone. (bmj.com)
  • Conclusion Evidence from randomised controlled trials is insufficient to show the superiority of combined cardiac resynchronisation and implantable cardioverter defibrillator therapy over cardiac resynchronisation therapy alone in patients with left ventricular impairment. (bmj.com)
  • Sudden cardiac deaths still account for about one third of all deaths in patients treated with resynchronisation therapy, w1 w2 and adding implantable cardioverter defibrillator backup to resynchronisation therapy might further reduce mortality. (bmj.com)
  • Recently, the implantable cardioverter-defibrillator (ICD) has been promoted for prevention of sudden death in hypertrophic cardiomyopathy (HCM). (nih.gov)
  • Cardiologic evaluation demonstrated unequivocal hypertrophic cardiomyopathy (HCM) and an internal cardioverter defibrillator (ICD) was implanted. (springer.com)
  • Implantable cardioverter defibrillators account for one-third of the decrease in cardiac arrests caused by ventricular fibrillation in North-Holland, according to research in Circulation, an American Heart Association journal. (redorbit.com)
  • ISO 14117:2012 specifies test methodologies for the evaluation of the electromagnetic compatibility (EMC) of active implantable cardiovascular devices that provide one or more therapies for bradycardia, tachycardia and cardiac resynchronization. (iso.org)
  • Based on product type, the market can be bifurcated into implantable and external defibrillators. (prnewswire.com)
  • In this report, the United States Implantable Cardioverter Defibrillator (ICD) market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. (reportsnreports.com)
  • What are the Indications of Implantable Cardioverter Defibrillator (ICD)? (medindia.net)
  • A retrospective cohort study of Medicare beneficiaries hospitalized for heart failure with a left ventricular ejection fraction between 30-35% found improved 3-year survival rates among those who received a prophylactic implantable cardioverter-defibrillators compared to those with no ICD. (hcplive.com)
  • Heart Failure: Should I Get an Implantable Cardioverter-Defibrillator (ICD)? (northshore.org)
  • NYHA Class II or III Heart Failure: Who Will Need an Implantable Cardioverter Defibrillator (ICD)? (scirp.org)
  • An intelligent patch electrode having a plurality of sensor electrodes for use with an implantable defibrillator. (freepatentsonline.com)
  • The number of implanted cardiac implantable electronic devices (CIED) has increased over the recent years [ 1 ]. (hindawi.com)
  • Objective While patients with cardiac implantable electronic devices could benefit from magnetic resonance (MR) imaging, the presence of such devices has been designated as an absolute contraindication to MR. Although scanning algorithms are proposed for cardiac implantable electronic devices, their safety remains uncertain. (bmj.com)
  • No lack of news on the implantable cardiac devices front these days. (medgadget.com)
  • Patients benefit from the teamwork of surgeons, cardiologists, interventional cardiologists, cardiovascular imaging experts and radiologists, and anesthesiologists, all experts in implantable cardioverter defibrillator (ICD) devices. (brighamandwomens.org)
  • Additionally, there is an increasing number of patients receiving implantable devices such as glucose sensors and orthopedic implants. (duke.edu)
  • Use of cardiac implantable electronic devices in older adults with cognitive impairment. (duke.edu)
  • Implantable devices which continuously monitor the electrical activity of the heart and automatically detect and terminate ventricular tachycardia (TACHYCARDIA, VENTRICULAR) and VENTRICULAR FIBRILLATION. (bioportfolio.com)
  • We included randomized controlled trials of fish-oil supplementation on ventricular fibrillation or ventricular tachycardia in patients with implantable cardioverter defibrillators. (cmaj.ca)
  • Budiodarone is being investigated as an anti-arrhythmic agent for the treatment of ventricular tachycardia (VT) in patients with an implantable cardioverter defibrillator (ICD). (prnewswire.com)
  • An implantable cardioverter-defibrillator ( ICD ) is a small battery -powered electrical impulse generator which is implanted in patients who are at risk of sudden cardiac death due to ventricular fibrillation and ventricular tachycardia . (wikidoc.org)
  • Concerns about the implantable cardioverter defibrillator: a determinant of anxiety and depressive symptoms independent of experienced shocks. (springer.com)
  • Analysis of troponin I levels after spontaneous implantable cardioverter defibrillator shocks. (biomedsearch.com)
  • The aim of this study was to assess the frequency and significance of elevated serum cTnI levels after spontaneous implantable cardioverter defibrillator (ICD) shocks. (biomedsearch.com)
  • Ladwig KH, Baumert J, Marten-Mittag B, Kolb C, Zrenner B, Schmitt C. Posttraumatic stress symptoms and predicted mortality in patients with implantable cardioverter-defibrillators: results from the prospective living with an implanted cardioverter-defibrillator study. (springer.com)
  • Sudden death in recipients of transvenous implantable cardioverter defibrillator systems: Terminal events, predictors, and potential mechanisms. (springer.com)
  • Effect of epinephrine on the efficacy of the internal cardioverter-defibrillator. (springer.com)
  • Should patients with severely impaired left ventricular function following myocardial infarction receive an implantable defibrillator? (mja.com.au)
  • This is the fourth decade that the implantable cardioverter-defibrillator (ICD) has been in clinical use for the prevention of sudden cardiac death in high-risk patients. (ahajournals.org)
  • Long Detection Programming in Single-Chamber Defibrillators Reduces Unnecessary Therapies and Mortality. (bostonscientific.com)
  • What do I need to know about implantable cardioverter defibrillator insertion? (drugs.com)
  • Our electrophysiologists and cardiovascular surgeons are experienced in implantable cardioverter-defibrillators (ICD) insertion techniques. (templehealth.org)